The role of drug disposition genes for variability in the pharmacokinetics of antiretroviral drugs by Zhang, Yuan
  
 
THE ROLE OF DRUG DISPOSITION GENES FOR 
VARIABILITY IN THE PHARMACOKINETICS OF 
ANTIRETROVIRAL DRUGS 
 
 
 
 
Thesis submitted in accordance with the requirement of the University of Liverpool 
for the degree of Doctor of Philosophy 
 
 
 
 
 
 
 
 
 
 
By 
Yuan Zhang 
January 2013 
 
This thesis is the result of my own work. The material contained within the thesis has 
not been presented, either wholly or in part, for any other degree or quantification. 
 
 
 
 
                                                           Yuan Zhang 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
This research was carried out in the 
 Liverpool HIV Pharmacology Group 
Department of Molecular and Clinical Pharmacology 
The University of Liverpool, UK 
 
 
 
 
ACKNOWLEDGEMENTS 
 
The studies presented in this thesis were carried out in the Department of 
Molecular and Clinical Pharmacology, University of Liverpool.  
 
I would like to thank Professor Andrew Owen, Professor David Back and 
Professor Saye Khoo for giving me the opportunity to pursue this 
research and for their supervision, guidance and support during my Ph.D. 
I am particularly grateful to my supervisor Professor Owen for his advice 
both technically and scientifically which were invaluable during the 
course of this project. 
 
I would like to thank Dr. Neill Liptrott and Deirdre Egan for the help with 
the pharmacogenetics work, Dr. John Tjia for his help with bioanalysis 
and Dr. Darren Smith for supporting me in the cell-based experimental 
research. I would also like to thank Dr. Marco Siccardi for giving me 
advice during my writing up. Thanks to everyone else in the Liverpool 
HIV Pharmacology Group for donating your time to help the completion 
of this thesis. 
 
Finally, I would like to thank my mum and dad for their constant love, 
support and encouragement throughout my study period. 
 
TABLE OF CONTENTS 
 
 Abbreviations 
 
i 
 Abstract 
 
 
 
iv 
Chapter 1 General Introduction 
 
1 
Chapter 2 Impact of nuclear receptors expression and single nucleotide 
polymorphisms on the gene expression of drug transporters in 
intestine 
 
33 
Chapter 3 Impact of nuclear receptors expression and single nucleotide 
polymorphisms on the gene expression of cytochrome P450 
enzymes in intestine 
 
83 
Chapter 4 Impact of drug concentrations on the viral load in patients 
receiving highly active antiretroviral therapy 
 
117 
Chapter 5 Impact of single nucleotide polymorphisms and copy number 
variations on efavirenz plasma concentrations 
 
147 
Chapter 6 Determination of Nano antiretroviral drugs transcellular 
permeability in Caco-2, MDCKII and MDCKII-ABCB5 cell 
lines 
 
178 
Chapter 7 Concluding Discussion 
 
199 
 References 206 
 
 
 
 
 
 
 
 
 
 
 
 
i 
 
ABBREVIATIONS 
 
μg Microgram(s) 
μl Microlitre(s) 
μM Micromolar 
ABC ATP binding cassette 
ACN Acetonitrile 
AIDS Acquired immunodeficiency syndrome 
AP Apical 
ART Antiretroviral therapy 
BL basolateral 
14
C Carbon radioisotope 
o
C Degrees centigrade 
Cmax Maximum plasma concentration 
Caco-2 Human colon adenocarcinoma cell line 
CAR Constitutive androstane receptor 
cART Combination antiretroviral therapy 
CCR5 CC chemokine receptor 5 
CD4(+) Helper T-lymphocyte antigen marker (expressing CD4) 
cDNA Complementary DNA 
CNV Copy number variation 
CRF Circulating recombinant forms 
Ct Cycle threshold 
CXCR4 CXC chemokine receptor 4 
CYP Cytochrome P450 
ddH2O Double-distilled water 
DMEM Dulbecco’s Modified Eagles Medium 
DMSO Dimethylsulphoxide 
DNA Deoxyribonucleic acid 
ii 
 
dsDNA Double strand DNA 
EDTA Ethylamine-diaminetetra-acetic acid 
EFV Efavirenz 
EI Entry inhibitors 
Env Envelope glycoprotein 
FBS Foetal bovine serum 
FDA US Food and Drug Administration 
g gram(s) 
GAPDH glyceraldehyde 3-phosphate dehydrogenase 
gDNA Genomic DNA 
gp41 Glycoprotein 41 
gp120 Glycoprotein 120 
h hour 
3
H Tritium 
HAART Highly active antiretroviral therapy 
HBSS Hanks Balance Salt Solution 
HIV human immunodeficiency virus 
HPLC High performance liquid chromatography 
HQC High quality control 
kg Kilogram(s) 
L Litre 
LPV Lopinavir 
LQC Low quality control 
M Molar 
MDCK Madin–Darby canine kidney 
MeOH methanol 
mg Milligram(s) 
MgCL2 Magnesium chloride 
min Minute(s) 
iii 
 
ml Millilitre 
mM Millimolar 
MQC Medium quality control 
mRNA Messenger RNA 
ng Nanogram(s) 
nm Nanometre(s) 
nM Nanomolar 
nmol Nanomole(s) 
NNRTI Non-nucleoside reverse transcriptase inhibitor 
NRTI Nucleoside reverse transcriptase inhibitor 
OATP Organic anion-transporting polypeptide 
PBMC Peripheral blood mononuclear cells 
PCR Polymerase chain reaction 
PI Protease inhibitor 
P-gp P-glycoprotein 
PK pharmacokinetic 
PXR pregnane X receptor 
qPCR Quantitative Polymerase Chain Reaction 
RFU relative fluorescence units 
RNA Ribonucleic acid 
RT Reverse transcriptase 
s Second(s) 
SD Standard deviation 
SNP Single nucleotide polymorphism 
TEER Trans Epithelial Electrical Resistance 
TDM Therapeutic drug monitoring 
UGT Uridine 5’diphosphate-glucuronosyltransferase 
v/v Volume to volume ratio 
VL Viral load 
iv 
 
ABSTRACT 
 
The failure of highly active antiretroviral therapy may be due to pharmacological 
factors such as drug transporters and metabolism enzymes. Drug transporters and 
metabolism enzymes played complementary roles in drug absorption, distribution, 
metabolism and excretion by biotransformation and counter-transport, particularly in 
the intestine while nuclear receptors as transcription factors regulate the expression of 
drug transporters and metabolism enzymes. In this thesis, a positive correlation 
between nuclear receptors expression and the expression of ABC transporters and 
OATP transporters in intestine were observed while a negative correlation was found 
between the gene expression of nuclear receptors and cytochrome P450 enzymes in 
intestine. Single nucleotide polymorphisms in genes could potentially impact on gene 
expression of drug transporters and metabolism enzymes. The polymorphisms of 
nuclear receptors were associated with the expression of ABC transporters. 
 
Drug concentrations have a high inter-individual variability in patients receiving the 
same dose of antiretroviral drugs, which could affect outcome of antiretroviral therapy. 
There are many factors that may affect plasma concentrations such as age, gender, 
body weight, ethnicity, genetic factors and so on. In a Ghanaian cohort, a negative 
correlation was found between the body weight and the EFV plasma concentration. 
Genetic factors such as the polymorphisms of cytochrome P450 enzymes also 
influenced efavirenz plasma concentrations. Meanwhile, efavirenz plasma 
concentrations were associated with the viral load in plasma within a UK cohort. 
 
Nanomedicine involves new and promising technologies that may enable and improve 
the targeted delivery of antiretroviral drugs. The permeability of lopinavir in the 
Caco-2 cell line was improved by formulation of nanodispersions. However, the 
permeability of efavirenz was decreased for all nanodispersions in MDCKII and 
MDCKII-ABCB5 cell lines. Comparing efficiency of efavirenz nanodispersions 
transcellular permeability in MDCKII and MDCKII-ABCB5 cell lines indicated that 
ABCB5 is able to transport efavirenz when incubated as dissolved molecule or 
nanodispersion. It is support by the copy number variation of ABCB5 had no 
relationship with EFV plasma concentrations. 
 
In summary, this thesis has attempted to determine the pharmacological factors 
influencing pharmacokinetics of HIV drugs, including drug transporters, metabolism 
enzymes and nuclear receptors. Data illustrating the factors that influence efavirenz 
plasma concentrations which are important for viral suppression were also generated. 
Furthermore, the nanodispersion technology is worthy of further study in order to 
improve drug delivery and drug distribution of antiretroviral drugs.  
 
 
 
  CHAPTER 1 
1 
 
 
 
 
 
 
 
CHAPTER 1 
 
General Introduction 
 
 
 
 
 
 
 
 
 
 
 
  CHAPTER 1 
2 
 
Contents 
 
1.1 Acquired Immunodeficiency Syndrome (AIDS) ................................................. 3 
1.2 Human Immunodeficiency Virus (HIV) .............................................................. 5 
1.2.1 Structure of HIV ................................................................................................... 5 
1.2.2 HIV replication cycle ............................................................................................ 7 
1.2.3 Variability of HIV ............................................................................................... 10 
1.3 Antiretroviral drugs ............................................................................................. 11 
1.3.1 Classes of drugs .................................................................................................. 11 
1.3.2 Combination therapy ........................................................................................... 15 
1.4 Drug Disposition................................................................................................... 16 
1.4.1 Phase I enzymes .................................................................................................. 17 
1.4.2 Influx and Efflux Transporters ............................................................................ 18 
1.4.3 Nuclear receptors ................................................................................................ 21 
1.5 Pharmacokinetics ................................................................................................. 26 
1.6 Pharmacogenetics ................................................................................................ 28 
1.7 Aim of Thesis ........................................................................................................ 31 
 
 
 
  CHAPTER 1 
3 
 
1.1 Acquired Immunodeficiency Syndrome (AIDS) 
Acquired immunodeficiency syndrome (AIDS) is a disease of the human immune 
system caused by the human immunodeficiency virus (HIV) (Sepkowitz, 2001). HIV 
destroys the immune system causing individuals to become susceptible to 
opportunistic infections and tumours. The transmission of HIV involves sexual 
intercourse (including oral and anal sex), contaminated blood transfusion and 
hypodermic needles, exchange between mother and baby during pregnancy, childbirth, 
breastfeeding or other exposure to bodily fluids (Albrektsson et al., 2009; Mole et al., 
2011; Stock, 2011). 
 
AIDS was first reported in 1981 by the U.S. Centres for Disease Control and 
Prevention (Gallo, 2006). Genetic research indicates that HIV originated in 
west-central Africa during the late nineteenth or early twentieth century (Sharp et al., 
2011). AIDS is now a pandemic disease in all over the world (Sharp et al., 2011). The 
Joint United Nations Programme on HIV and AIDS (UNAIDS) estimated that there 
were 34 million people worldwide living with HIV/AIDS in 2010 from the report of 
UNAIDS 2011. There is a 27% increase compared with 26.2 million in 1999 from the 
global report of UNAIDS 2010 (UNAIDS, 2010). Meanwhile, 2.6 million people 
were newly infected with HIV in 2009 which is more than one fifth (21%) fewer than 
the estimated 3.2 million in 1997 (Table 1.1). The number of annual AIDS-related 
deaths worldwide is steadily decreasing from 2.1 million in 1997 to an estimated 1.8 
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million in 2009 (Table 1.1). Data have shown that the treatments for HIV decrease the 
number of people that die due to AIDS. Antiretroviral treatment reduces both the 
mortality and the morbidity of HIV infection, but there is no drug which can cure the 
patients and a vaccine has not been found (May et al., 2011). Cost of therapy is 
another difficulty for treating HIV infection in many countries. Therefore the 
prevention of infection is a core objective to control the AIDS pandemic. Many 
programmes which attempt to slow the spread of the virus such as safe sex and 
needle-exchange have been promoted by the health organizations (Wasnik, 2011). 
 
Table 1.1 the number of people infected with HIV and death due to AIDS 
Year 1970-2009 1990 1997 2009 Reference 
HIV 
infections 
65,000,000 2,100,000 3,200,000 2,600,000 (UNAIDS, 
2011) 
AIDS-related 
Death 
29,000,000 300,000 2,100,000 1,800,000 (UNAIDS, 
2011) 
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1.2 Human Immunodeficiency Virus (HIV) 
HIV is a lentivirus which is a member of the retrovirus family (Gonda, 1988; Volsky, 
1990). Two types of HIV have been characterized: HIV-1 and HIV-2. HIV-1 is the 
virus that was initially discovered which is more virulent and infective (Gilbert et al., 
2003). HIV-1 infections are of global prevalence, while HIV-2 has a lower virulence 
and infectivity compared to HIV-1. Because of its relatively poor capacity for 
transmission, HIV-2 is largely confined to West Africa (Almaghrabi et al., 2011). 
 
1.2.1 Structure of HIV 
HIV is larger than other viruses and its structure is different from other retroviruses. It 
is roughly spherical with a diameter of about 120 nm (Campbell et al., 2001). Two 
copies of positive single-stranded RNA that codes for the virus's nine genes are 
enclosed by a conical capsid which is made by the viral protein p24 
(Berthet-Colominas et al., 1999). There are also some enzymes including reverse 
transcriptase, protease, ribonuclease and integrase in the capsid. A matrix composed 
of the viral protein p17 surrounds the capsid ensuring the integrity of the virion 
particle (Ellenrieder et al., 2004). The virion is surrounded by a viral envelope which 
is a membrane with a phospholipid bilayer that comes from the host cell. An envelope 
glycoprotein (Env) composed of a cap made by three receptor binding domain gp120 
and surface fusion protein subunit gp41 is embedded in the virus, which catalyzes 
virus entry and is a major target for therapeutic intervention and for neutralizing 
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antibodies (Buzon et al., 2010)(Figure 1.1).  
 
 
 
Figure 1.1 structure of HIV 
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1.2.2 HIV replication cycle 
The replication cycle of HIV is shown in Figure 1.2. HIV can infect a variety of 
immune cells such as CD4+ T cells, macrophages, and the other cells with CD4 on its 
surface (Cunningham et al., 2010). 
 
When HIV gains entry to macrophages and CD4+ T cells, it is mediated through 
interaction of the virion envelope gp120 not only with the CD4 molecule but also with 
chemokine co-receptors CCR5 or CXCR4 on the target cells. The envelope complex 
of the virus undergoes a structural change after gp120 is bound with the CD4 protein. 
The chemokine binding domains of gp120 are then exposed and interact with CCR5 
or CXCR4 on the host cell membrane (Fanales-Belasio et al., 2010). When the 
N-terminal fusion peptide gp41 penetrates into the host cell membrane there is a 
change in the structure to a hairpin (Fanales-Belasio et al., 2010). This loop structure 
brings the virus and cell membranes close together, allowing fusion of the membranes 
and subsequent entry of the viral capsid (Fanales-Belasio et al., 2010). 
 
After HIV fusion with the target cell, the virus RNA and various enzymes (including 
reverse transcriptase, integrase, ribonuclease, and protease) are injected into the host 
cell. Before transporting to the nucleus, the viral single-strand RNA is transcribed into 
double-stranded DNA by reverse transcriptase. The viral DNA is then integrated into 
the host cell genome by the enzyme integrase. This integrated DNA provirus may then 
lie dormant, in the latent stage of HIV infection (Zheng et al., 2005).  
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Activation of the host cell results in the transcription of viral DNA into viral 
messenger RNA (mRNA). These viral mRNA are exported from the nucleus into the 
cytoplasm where they are translated into the viral proteins (Klimas et al., 2008). 
These viral proteins are cleaved by HIV protease and localise with the viral RNA 
exported from the nucleus (Klimas et al., 2008). The structural proteins are produced 
from the full-length mRNA which includes the virus genome. The genome then 
assembles with the proteins and is packaged into new virus particles, which bud 
through the host cell membrane. After acquiring a new envelope the virions are 
released into the extracellular space where they continue to mature (Fanales-Belasio 
et al., 2010).  
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Figure1.2 HIV replication cycle dsDNA: double strand DNA 
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1.2.3 Variability of HIV 
HIV is different from many viruses because it has very high variability. This diversity 
is a result of the “error-prone” mechanism of action of the virus enzyme reverse 
transcriptase (Sarafianos et al., 2009), the very rapid viral replication and the 
occurrence of recombination processes between two or more different HIV viruses 
within the same infected individual (Fanales-Belasio et al., 2010).  
 
HIV can be divided into two major types, HIV-1 and HIV-2. HIV-1 is related to 
viruses found in chimpanzees and gorillas living in western Africa, while HIV-2 
viruses are related to viruses found in sooty mangabeys. HIV-1 viruses may be further 
divided into groups, M (Major), O (Outlier) and N (non-M/non-O). The HIV-1 group 
M viruses predominate and are responsible for the AIDS pandemic. It is further 
subdivided into subtypes. Different subtypes can also be recombined as circulating 
recombinant forms (CRFs) such as CRF12_BF which is a recombination between 
subtypes B and F. Group O and Group N are rare but many HIV-positive samples 
have been found. It could not be detected by early versions of the HIV-1 test kits but 
more advanced HIV tests have now been developed to detect both Group O and 
Group N viruses (Aghokeng et al., 2009). Likewise, HIV-2 can also be subdivided 
into a number of major groups. As of 2010, there are 8 known HIV-2 groups (A to H). 
Of these, only groups A and B are epidemic. Group A spread mainly in West Africa, 
but also to Angola, Mozambique, Brazil, India, and very limitedly to Europe and the 
US. Group B is mainly confined to West Africa (Hodges-Mameletzis et al., 2011). 
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1.3 Antiretroviral drugs 
1.3.1 Classes of drugs 
Antiretroviral (ARV) drugs are primarily medications used for the treatment of HIV 
infection. They are broadly classified into five categories according to the phase of the 
HIV life-cycle (Table 1.2).  
 
Entry inhibitors (EI) 
Entry inhibitors interfere with the binding, fusion and entry of an HIV virion into a 
human cell. Enfuvirtide is the first and only HIV fusion inhibitor which is used in 
combination therapy for the treatment of HIV-1 infection (Cervia et al., 2003). 
However, use of enfuvirtide is limited due to its availability only as a parenteral 
administration (Avelino-Silva et al., 2012). CCR5 receptor antagonists are the first 
antiretroviral drugs which do not target the virus directly. Instead, they bind to the 
CCR5 receptor on the surface of the T-Cell and block viral attachment to the cell. 
Most strains of HIV attach to T-Cells using the CCR5 receptor. Therefore, the virus 
cannot gain entry to replicate when CCR5 is blocked by the antagonist. Currently the 
only available co-receptor antagonist is maraviroc, but others are in development. A 
limitation of this class of drug is that a HIV tropism test such as a Trofile Assay is 
required to ensure the patient doesn’t harbour CXCR4-utilising strains of virus. This 
adds an additional cost to therapy 
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Reverse transcriptase inhibitors (RTIs) 
RTIs are a class of antiretroviral drug used to treat HIV infection, which inhibit 
activity of reverse transcriptase, a viral DNA polymerase enzyme that retroviruses 
need to reproduce. There are two types of RTIs: Nucleoside and nucleotide reverse 
transcriptase inhibitors (NRTIs) and Non-nucleoside reverse transcriptase inhibitors 
(NNRTIs). NRTIs inhibit reverse transcription by being incorporated into the newly 
synthesized viral DNA strand as a “faulty” nucleotide. This causes a chemical reaction 
resulting in DNA chain termination. NNRTIs inhibit reverse transcriptase directly by 
binding to the enzyme and interfering with its function. Therefore, NRTIs are 
competitive inhibitors whereas NNRTIs are non-competitive inhibitors. NRTIs 
compose the first class of antiretroviral drugs developed, for example, zidovudine, 
didanosine, abacavir, tenofovir, apricitabine and so on (Table 1.2). Non-nucleoside 
reverse-transcriptase inhibitors (NNRTIs) are the third class of antiretroviral drugs 
that were developed and include efavirenz, nevirapine, delavirdine, etravirine and 
rilpivirine.  
 
Protease inhibitors (PIs)  
Protease inhibitors (PIs) are a class of medications used to treat or prevent infection 
by viruses, including HIV and Hepatitis C. PIs prevent viral replication by inhibiting 
the activity of HIV-1 protease, an enzyme used by the viruses to cleave nascent 
proteins for final assembly of new virions. In antiretroviral therapy, PIs include 
saquinavir, lopinavir, darunavir, atazanavir, ritonavir and so on (Table 1.2). 
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Antiretroviral PIs are substrates for multiple transport and metabolism proteins such 
as CYP3A isoforms (Josephson et al., 2007), ABCB1, ABCC1 and ABCC2 (Jain et 
al., 2007). 
 
Integrase inhibitors 
Integrase inhibitors are a class of antiretroviral drug designed to block the action of 
integrase, a viral enzyme that inserts the viral genome into the DNA of the host cell. 
The first integrase inhibitor approved by the U.S. Food and Drug Administration 
(FDA) was raltegravir, approved on October, 2007 (Steigbigel et al., 2008). 
Raltegravir has an unusual pharmacokinetic - pharmacodynamic relationship and 
erratic absorption due to different solubility at different pH (Cattaneo et al., 2012). 
Many other integrase inhibitors are now in development. 
 
Maturation inhibitors 
Maturation inhibitors inhibit the last step in gag processing in which the viral capsid 
polyprotein is cleaved, thereby blocking the conversion of the polyprotein into the 
mature capsid protein (p24). To date, these are experimental agents and no clinically 
used drugs in this class have been licensed (Martin et al., 2008; Myriad-Genetics, 
2010; Myriad-Genetics, 2008). 
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1.3.2 Combination therapy 
HIV treatment combines several drugs, typically three or four. This combination 
therapy is known as Highly Active Antiretroviral Therapy (HAART). The life cycle of 
HIV can divide into four stages: entry to the cell, replication and transcription, 
assembly, and release of additional viruses. The different classes of antiretroviral 
drugs act on different stages of the HIV life-cycle. Drug combinations can improve 
the effectiveness of the antiretroviral drugs and prevent multi-drug resistance 
emerging. The key aim of the antiretroviral combination therapy is to defend against 
resistance by suppressing HIV replication as much as possible. 
 
Combinations of antiretroviral drugs can decrease resistance because if a mutation 
conferring resistance to one drug emerges, the other drugs can continue to suppress 
reproduction of that mutant. Combinations usually comprise two NRTIs and one 
NNRTI or PI (Ghosh et al., 2011). Because the combinations of antiretroviral drugs 
are subject to positive and negative synergies, the total number of combination drugs 
must be limited. For example, the combination of didanosine and zidovudine was 
highly cytotoxic and mutagenic (Walker et al., 2009). 
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1.4 Drug Disposition 
The pharmacological action of oral drugs is dependent on adequate intestinal 
absorption, distribution to sites of action, and elimination by metabolic and excretory 
pathways. Drug metabolism reactions are generally divided into 2 phases, Phase I and 
Phase II. Phase I reactions are primarily mediated by the cytochrome P450 enzymes 
(Zollner et al., 2010). The drugs are oxidized, reduced and hydrolysed by different 
enzymes. In Phase II reactions, the drugs (or Phase I metabolites) conjugate with 
some endogenous compounds, such as glucuronic acid, glutathione or sulphate so that 
they can be more readily excreted (Mottino et al., 2000). Through targeted expression 
in organs (intestine, kidney, and liver), transporters also have a significant impact on 
the drug disposition process. Therefore, transporters, enzymes, the drug pKa, 
molecular weights, lipophilicity and other physicochemical properties can all affect 
the extent of drug absorption and access to target tissues. 
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1.4.1 Phase I enzymes 
Cytochrome P450 is a very large and diverse superfamily of haem containing proteins 
found in all domains of life (Danielson, 2002). These enzymes are the major enzymes 
involved in drug metabolism and bioactivation, accounting for about 75% of the total 
metabolism (Wang et al., 2010). CYP2B6 can metabolise approximately 8% of 
clinically used drugs, including efavirenz, nevirapine, cyclophosphamide, ifosfamide, 
tamoxifen, ketamine, artemisinin, bupropion, sibutramine, and propofol (Mo et al., 
2009). CYP3A4 metabolises approximately 50% of the marketed drugs including 
antiretroviral agents such as the PIs and certain NNRTIs (Kumar et al., 2011). Many 
substances are bioactivated by Cytochrome P450 enzymes to form their active 
compounds. In HAART, the NNRTI efavirenz is a substrate of CYP2B6 and 
nevirapine is a substrate for both CYP2B6 and CYP3A4. The second-generation 
NNRTI etravirine is also a substrate of CYP3A4 (Tseng et al., 2010).  
 
Several PIs such as indinavir, darunavir, lopinavir, saquinavir, atazanavir, tipranavir 
and ritonavir are all predominantly metabolised by CYP3A4 (Kumar et al., 2011). 
Cytochrome P450 enzymes are present in many tissues of the body including 
hepatocytes, lymphocytes and the mucosa of the gastrointestinal tract (Fagiolino et al., 
2011). CYP3A4 constitutes 80% of total intestinal CYP protein expression, followed 
by CYP2C at 18%, and that CYP2B6 expression is relatively minor – however this 
will still be important if the absorption and distribution of a drug is heavily dependent 
on CYP2B6 (Thelen et al., 2009).  
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1.4.2 Influx and Efflux Transporters 
Both influx and efflux transporters are important in determining oral drug disposition 
by controlling absorption and bioavailability. See Figure 1.3 and 1.4 for their 
localization in enterocytes and hepatocytes and Table 1.3 for examples of substrates 
for those transporters expressed in tissue. The major influx transporters responsible 
for xenobiotic transport belong to the two solute carrier superfamilies. In this thesis, 
we focused on the Organic anion-transporting polypeptide (OATP) superfamily 
transports. OATP transporters are plasma membrane transport proteins that mediate 
the active cellular influx of a variety of amphipathic compounds (Pacyniak et al., 
2010). Substrates include bile salts, steroid conjugates, thyroid hormones, anionic 
oligopeptides and several therapeutic drugs and other xenobiotics (Leuthold et al., 
2009). PIs but not NNRTIs have also been shown to be substrates for these 
transporters (Hartkoorn et al., 2010). OATP transporters are expressed in various cells 
and tissues such as the liver, kidneys, intestine and the blood–brain barrier (Table 1.3), 
and therefore, may significantly affect the pharmacokinetics and distribution of their 
substrate drugs.  
 
Efflux transporters expressed in the intestine and liver include P-glycoprotein (P-gp, 
ABCB1), bile salt export pump (BSEP, ABCB11), multidrug resistance proteins 
(MRP1- 6, ABCC1-6), and breast cancer resistance protein (BCRP, ABCG2), all 
members of the ATP-Binding Cassette superfamily (Choudhuri et al., 2006; Kosters et 
al., 2008). Members of this superfamily use ATP as an energy source, allowing them 
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to pump substrates against a concentration gradient. These proteins transport various 
compounds (e.g. lipids and sterols, ions and small molecules, drugs, and large 
polypeptides) across extra- and intracellular membranes (Dean et al., 2001). Therefore, 
the ABC transporters play an important role in pharmacokinetics of numerous drugs 
through their expression in the intestine, liver, and kidney (Table 1.3). They do this by 
limiting absorption in the gut and so reducing the bioavailability, controlling the drug 
elimination into bile, urine, and faeces, and restricting the drug distribution to 
modulate the effectiveness of the drug therapy (Albermann et al., 2005). They are also 
known to play a crucial role in conferring the development of multidrug resistance in 
cancer (Calcagno et al., 2008). Transporters can also be involved in drug-drug 
interactions, which can potentially increase or decrease drug concentrations in plasma 
and/or tissues (Calcagno et al., 2007; Ding et al., 2004; Staud et al., 2010). Activity of 
ABC-transporters is highly variable and may be altered within hours by inhibitors and 
within days by inducing agents. Also, genetic influences or endogenous factors like 
sex-hormones (Calcagno et al., 2008) or cholesterol (Aarnoudse et al., 2008) might 
influence transporter activity. Many ABC transporters are expressed in intestine, for 
example ABCG2 was identified as the most abundantly expressed transporter in the 
intestinal mucosa and ABCB1, ABCC1 and ABCC2 were highly expressed in jejunal 
tissue (Hilgendorf et al., 2007). ABCC10 are expressed in a wide range of normal 
tissues including colon (Oguri et al., 2008). A number of efflux transporters belonging 
to the ABC superfamily, are able to transport antiretroviral drugs. ABCG2 has 
significant inhibition for antiretroviral drugs such as lopinavir, nelfinavir, delavirdine, 
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efavirenz, saquinavir and so on (Weiss et al., 2007a). ABCB1 have been implicated in 
the efflux of some antiretroviral drugs (Chandler et al., 2007). ABCC1, ABCC2, and 
ABCC3 inhibit antiretroviral drugs including Nucleoside, Nucleotide, and 
Non-Nucleoside Reverse Transcriptase Inhibitors (Weiss et al., 2007b). ABCC10 is 
substrate for antiretroviral drugs (e.g. zalcitabine, tenofovir and nevirapine) (Liptrott 
et al., 2012). These proteins may thus influence antiretroviral drug therapy by their 
effect on pharmacokinetics and by promoting drug resistance (Borst et al., 2004). In 
my thesis, we focused on transporters for which NNRTIs and PIs were substrates. 
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1.4.3 Nuclear receptors 
Nuclear receptors are a class of proteins found within the interior of cells that are 
responsible for sensing the presence of steroid and thyroid hormones and certain other 
molecules. In response, these receptors work in concert with other transcription 
factors to regulate the expression of specific genes, thereby controlling development, 
homeostasis, and metabolism within the organism. Nuclear receptors have the ability 
to directly bind to DNA and regulate the expression of adjacent genes, hence these 
receptors are classified as transcription factors (Olefsky, 2001).  
 
The pregnane X receptor (PXR) is a nuclear receptor whose primary function is to 
sense the presence of foreign toxic substances and, in response, up-regulate the 
expression of proteins (e.g. enzymes and transporters) involved in the detoxification 
and clearance of these substances from the body (Kliewer et al., 2002). The 
constitutive androstane receptor (CAR) is also a member of the nuclear receptor 
superfamily, which also regulates the transcription of target genes involved in drug 
metabolism such as the cytochrome P450 family and transporters (Kakizaki et al., 
2008).  
 
PXR and CAR bind as heterodimeric complexes with the retinoid X receptor to 
response elements in the regulatory regions of the induced genes. PXR is directly 
activated by xenobiotic ligands, whereas CAR is involved in a more complex and less 
well understood mechanism of signal transduction triggered by drugs. One of the 
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primary targets of PXR activation is the induction of CYP3A4, an important phase I 
oxidative enzyme (Sandanaraj et al., 2008). In addition, PXR up regulates the 
expression of phase II conjugating enzymes such as glutathione S-transferase (Swales 
et al., 2011) and phase III transport uptake and efflux proteins such as ABCB1, 
ABCC2, ABCC3 and OATP2 (Kast et al., 2002; Staudinger et al., 2001; Teng et al., 
2003). PXR can up-regulate both ABC transporters (ABCB1 and ABCC2) and OATP 
transporters by rifampicin (Peters et al., 2011). Meanwhile, PXR also directly 
influences the basal expression levels of the ABC transporters (ABCB1, ABCC1, 
ABCC2 and ABCC10) and OATP transporters in liver and intestine (Albermann et al., 
2005; Svoboda et al., 2011; Xu C., 2005). CAR appears to be responsible for 
induction of ABCC2 mRNA in human hepatocytes (Kast et al., 2002). CAR is 
co-expressed with and co-regulates ABC transporters (ABCB1, ABCC1, ABCC2 and 
ABCC10) and OATP transporters in intestine and liver (Svoboda et al., 2011; Xu C., 
2005). CAR are also known to regulate gene expression of CYP2B6 and CYP3A4 
(Hasegawa et al., 2010; Rhodes et al., 2011) and its expression correlates with 
CYP2B6 gene expression in liver (Chang et al., 2003).  
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Figure 1.3 Enterocyte with intestinal influx (white) and efflux (black) 
transporters. P-glycoprotein (P-gp), Multidrug resistance protein (MDR), Multidrug 
resistance associated protein (MRP), Breast cancer resistance protein (BCRP), 
Monocarboxylate transporter protein (MCT), Peptide transport protein (PEPT), 
Organic anion transporting polypeptide (OATP), Organic cation transporter (OCT), 
apical sodium-dependent bile acid transporter (ASBT), Concentrative nucleotide 
transporter (CNT), Electroneutral organic cation transporter (OCTN), Equilibrative 
nucleoside transporter (ENT). Adapted from Custodio et al (Custodio et al., 2008). 
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Figure 1.4 Hepatocyte with hepatic influx (white) and efflux (black) transporters. 
P-glycoprotein (P-gp), Multidrug resistance protein (MDR), Multidrug resistance 
associated protein (MRP), Breast cancer resistance protein (BCRP), Bile salt export 
pump (BSEP), Organic cation transporter (OCT), Organic anion transporter (OAT), 
Organic anion transporting polypeptide (OATP), sodium-taurocholate cotransporting 
polypeptide (NTCP). Adapted from Custodio et al (Custodio et al., 2008) 
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1.5 Pharmacokinetics 
Pharmacokinetics is a fundamental scientific discipline that underpins applied 
therapeutics. It describes the movement of a drug around the body and shows what the 
body is doing to the drug. Understanding of pharmacokinetics should help to 
appreciate how dosage regimens are devised, design a dosage regimen to the 
individual requirements of a patient and determine what is wrong when a patient fails 
to respond to treatment. It is also important to find out why a drug has caused toxicity 
and elucidate the mechanisms of drug interactions. Pharmacokinetics provides a 
mathematical basis to assess the time course of drugs and their effects in the body. It 
enables the following processes to be quantified: Absorption, Distribution, 
Metabolism and Excretion (ADME). Bioavailability, clearance and volume of 
distribution are three key parameters for pharmacokinetics. 
 
The variability in pharmacokinetics may arise from several factors such as genetics, 
disease (e.g. fever, congestive heart failure, gastrointestinal and hepatic), age, body 
weight, gender, food, environment (e.g. smoking and pollutants) and co-administered 
drugs (Becker et al., 2002; Lane et al., 2012; van den Anker et al., 2011). After a drug 
is administered orally, the plasma concentrations change over a period of time. The 
marked inter-individual variability in drug concentrations and the relationship 
between plasma drug concentrations and efficacy or toxicity make antiretroviral drugs 
candidates for therapeutic drug monitoring (Back et al., 2006). Intracellular 
concentrations of NNRTIs and PIs may be an important determinant of antiviral 
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activity, and the pharmacokinetics of intracellular drug accumulation is likely to 
impact upon efficacy and toxicity (Owen et al., 2004). The plasma drug levels of PIs 
and NNRTIs correlate with viral suppression and drug toxicity (Fraaij et al., 2005). 
Most of the PIs display poor pharmacokinetic properties because they are substrates 
of cytochrome P450 3A4 (Bazzoli et al., 2010) and transporters (Bierman et al., 2010; 
Hartkoorn et al., 2010). Variability in the plasma concentration of efavirenz and 
nevirapine is associated with the therapeutic effect on patients (Darwich et al., 2008). 
Plasma efavirenz levels are associated with efavirenz efficacy (Yimer et al., 2011) 
and central nervous system toxicity (van Luin et al., 2009). 
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1.6 Pharmacogenetics 
Pharmacogenetics is the branch of pharmacology which deals with the influence of 
genetic variation on drug response in patients by correlating gene expression or single 
nucleotide polymorphisms (SNP) with a drug's pharmacokinetics efficacy or toxicity. 
By doing so, pharmacogenetics aims to develop rational means to optimize drug 
therapy, ensuring maximum efficacy with minimal adverse effects. Such approaches 
promise the advent of "personalized medicine", in which drugs and drug combinations 
are optimized for each individual's unique genetic makeup.  
 
CYP2B6 is responsible for the metabolic clearance of efavirenz and CYP2B6 516TT 
are associated with efavirenz pharmacokinetics in the cohort of the German (Wyen et 
al., 2011). CYP2B6 516TT genotype increased the plasma efavirenz and nevirapine 
concentrations in Thai cohort (Uttayamakul et al., 2010). However, in other studies, 
CYP2B6 516GG genotype decreased the plasma efavirenz concentrations but not 
nevirapine, while CYP3A4 polymorphisms had no significant impact on plasma 
efavirenz or nevirapine concentrations in a Chinese patient population (Chen et al., 
2010). UGT2B7*1a and CYP2A6 (*9 and *17) carrier status increased efavirenz 
plasma concentrations (Kwara et al., 2009). Finally, CAR-CC (rs2307424) also 
correlates with efavirenz plasma concentrations in German cohort (Wyen et al., 2011). 
 
Previous pharmacogenetics studies have not provided sufficient data to explain 
variability of PI pharmacokinetics in patients (Granfors et al., 2006; van Erp et al., 
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2007). Ritonavir is an inhibitor for many of the proteins that have been identified as 
pharmacogenetic targets and ritonavir is usually given in combination with other 
antiretroviral drugs. For example, CYP3A5 is an important determinant of the 
pharmacokinetics of saquinavir but CYP3A polymorphisms do not influence of PI 
pharmacokinetics. This may be because ritonavir is a potent inhibitor of CYP3A4/5 
(Josephson et al., 2007). PIs are also substrates for ABCB1 and ritonavir is also an 
inhibitor of ABCB1. Therefore, it is difficult to explain why ABCB1 polymorphisms 
would influence protease inhibitor exposure (Jain et al., 2007). The ability of ritonavir 
to competitively inhibit transporters and metabolising enzymes has lead to its use as a 
“booster” during therapy with PIs. OATP transporters such as OATP1B1, OATP1B3 
and OATP1A2 have been reported to use PIs as substrates and OATP1B1 SNPs are 
associated with lopinavir pharmacokinetics (Hartkoorn et al., 2010; Su et al., 2004). 
Genome wide association study show the PGx link between OATP1B1 expression and 
the risk of statin-induced myopathy for simvastatin (Link et al., 2008). Currently there 
are no guidelines regarding fold change in AUC that is indicative of clinically 
significant genetic associations. However, for a drug-drug interaction, higher than 
5-fold difference in AUC is defined by the FDA as a strong interaction.   
 
A PXR-TT (PXR C63396T) increased Atazanavir clearance through an effect on 
hepatic PXR expression and therefore expression of its target genes (e.g. CYP3A4, 
ABCB1and OATP1B1), which are known to be involved in Atazanavir clearance 
(Schipani et al., 2010). PXR*1B haplotype constitution could be important in 
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decreasing doxorubicin clearance through reduced hepatic mRNA expression of PXR 
and its downstream targets (Sandanaraj et al., 2008). PXR and CAR polymorphisms 
regulate the expression of OATP1B (OATP1B1 and OATP1B3) transporters both in 
vitro and in vivo (Meyer zu Schwabedissen et al., 2009).  
 
As PXR regulates cytochrome P450 enzymes, the PXR polymorphisms have revealed 
not only changes in PXR expression and activity, but also effects on CYP3A4 gene 
expression (Svard et al., 2010). PXR polymorphism was associated with significantly 
lower expression of CYP3A4 in liver tissues (Sandanaraj et al., 2008). In 
antiretroviral therapy, several drugs including darunavir, fosamprenavir, lopinavir, 
nelfinavir, tipranavir, efavirenz, and abacavir increased the expression of cytochrome 
P450 enzymes through PXR (Svard et al., 2010).  
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1.7 Aim of Thesis 
It is well recognised that different patients respond in different ways to the same 
medication. These differences are often greater among members of a population than 
they are within the same person at different times (or between monozygotic twins). 
The existence of large population differences with small intra-patient variability is 
consistent with inheritance as a determinant of drug response. Although many factors 
influence drug response, including age, organ function, concomitant therapy, 
drug–drug interactions, and the nature of the disease, it is estimated that genetics can 
account for 20–95 percent of the variability in drug disposition and response (Kalow 
et al., 1999). Once a drug is administered, it is absorbed and distributed to its site of 
action, where it interacts with targets (such as receptors and enzymes), undergoes 
metabolism, and is then excreted. Each of these processes influences the drug 
response and can potentially involve clinically significant genetic variation. The field 
of pharmacogenetics began with a focus on drug metabolising enzymes (Meyer, 2004; 
Weinshilboum, 2003), and then extended to membrane transporters that influence 
drug absorption, distribution, and excretion (Evans et al., 2003; Fischer et al., 2005; 
Gerloff, 2004; Kerb et al., 2001; Kim, 2002; Roden et al., 2002). 
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The main aims of this thesis are to investigate the role of drug disposition genes for 
variability in the pharmacokinetics of antiretroviral drugs. The design of the studies 
was as follows: 
 
 Evaluation of the impact of nuclear receptor expression and single nucleotide 
polymorphisms on the expression of drug transporters in intestine 
 Investigation of the impact of nuclear receptor expression and single 
nucleotide polymorphisms on the expression of cytochrome P450 enzymes in 
intestine 
 Determination of the influence of drug concentration on the viral load in 
patients receiving highly active antiretroviral therapy  
 Assessment of the effects of single nucleotide polymorphisms and copy 
number variations on efavirenz plasma concentrations 
 Comparison of nanodispersions and aqueous solutions of antiretroviral drugs 
with respect to transcellular permeability in Caco-2, MDCKII and 
MDCKII-ABCB5 cell lines 
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2.1 INTRODUCTION 
Since the discovery of P-gp in 1976 (Juliano et al., 1976), the importance of drug 
transporters in influencing the pharmacokinetics of orally dosed drugs has become 
increasingly evident (Fromm, 2000; Landowski et al., 2003; Mizuno et al., 2002). 
Drug transporters in both the gut and the liver can help control access of drugs to 
systemic circulation by dictating the amount of drug that enters the body from the gut 
lumen and influencing how much drug escapes first pass metabolism in both gut and 
liver. Distribution of therapeutic compounds in vivo can be affected by transport 
across cell membranes by drug transporters. For example, ABC transporters can 
actively restrict drug distribution to the site of action by drug efflux from the cell via 
an ATP-dependant mechanism. Probably the best studied ABC transporter is ABCB1 
(P-glycoprotein). ABCB1 is capable of expelling many hydrophobic compounds 
including chemotherapeutic agents (e.g. etoposide, doxorubicin, and vinblastine), 
immunosuppressive agents (e.g. cyclosporine A, methotrexate) and HIV-type 1 
antiretroviral therapy agents like protease inhibitors and non-nucleoside reverse 
transcriptase inhibitors (NNRTI). ABCB1 is extensively distributed and expressed in 
many tissues of the body including in the kidney on the apical side of the intestinal 
lumen, the apical side of the bile canaliculus in liver hepatocytes, the apical 
membrane of proximal tubule epithelial cells and the apical side of the capillaries in 
the blood brain barrier (BBB). (Carl et al., 2010; Chai et al., 2011; Daood et al., 2008; 
He et al., 2011; Jung et al., 2011; Wright et al., 2004).  
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ABCC1 is expressed in the liver, kidney, intestine, brain and other tissues (He et al., 
2011) and it is localized to the basolateral membrane in intestinal epithelium 
(Beedholm-Ebsen et al., 2010), hepatocytes (Fülöp et al., 2008), Henle loop of kidney 
(Wright et al., 2004) and choroid plexus epithelium of the blood-cerebrospinal fluid 
barrier (Daood et al., 2008). ABCC1 is associated with tumour resistance which is 
often caused by an increased efflux and decreased intracellular accumulation of 
natural product anticancer drugs and other anticancer agents (He et al., 2011). ABCC2 
is expressed mainly in the apical membrane of liver canaliculi, renal proximal tubules, 
gut enterocytes, placenta, and brain-blood barrier (Lai et al., 2007). ABCC10 is highly 
expressed in liver, intestine, and peripheral blood cells (Liptrott et al., 2012) and 
localizes to the basolateral cell surface (Malofeeva et al., 2012). Similar to ABCC1, 
ABCC2 and ABCC10 are also associated with the resistance of anticancer drugs 
(Chen et al., 2009; Zhou et al., 2009). In my thesis, we focused on transporters for 
which NNRTIs and PIs were substrates. Although ABCG2 was identified as the most 
abundantly expressed transporter in the intestinal mucosa (Hilgendorf et al., 2007) 
ABCG2 has been shown to transport NRTIs but this wasn’t a focus of my thesis 
(Weiss et al., 2007). 
 
OATP transporters are expressed in various cells and tissues, some members show a 
more restricted pattern (well-studied OATP1B1/OATP1B3 in liver, OATP4C1 in 
kidney, and OATP6A1 in testis) (Svoboda et al., 2011). Intestinal epithelia contain in 
their apical (luminal) membrane several uptake transporters including one or more 
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members of the organic anion transporting polypeptide (OATP) family (Giacomini et 
al., 2010). Three members of the OATP family (OATP1B1, OATP1B3 and OATP2B1) 
localize in the basolateral membrane of human hepatocyte, one member (OATP4C1) 
in kidney proximal tubule epithelia and two members (OATP1A2 and OATP2B1) in 
apical membrane of brain capillary endothelial cells (Giacomini et al., 2010).  
 
Nuclear receptors, including CAR and PXR, regulate hepatic and intestinal 
transporters in response to exogenous and endogenous activators (Martin et al., 2008).  
PXR can modulate and/or up-regulate both ABC transporters (ABCB1 and ABCC2) 
and OATP transporters by rifampicin (Peters et al., 2011). Meanwhile, PXR also 
directly influences the basal expression levels of the ABC transporters (ABCB1, 
ABCC1, ABCC2 and ABCC10) and OATP transporters in liver and intestine, in a 
cell- and tissue-specific way (Albermann et al., 2005; Svoboda et al., 2011; Xu C., 
2005). CAR is co-expressed with and co-regulates ABC transporters (ABCB1, 
ABCC1, ABCC2 and ABCC10) and OATP transporters in intestine and liver, also in a 
cell- and tissue-specific way (Svoboda et al., 2011; Xu C., 2005).  
 
 
Polymorphisms within regulatory sequences at the 5’ and 3’ ends of the gene may 
affect transcription by altering the structure of transcription factor binding sites 
(Scotto, 2003). Polymorphisms occurring in introns may affect mRNA splicing, if at 
the ends of the intron, or the structure of enhancers or silencers (Tabara et al., 2002). 
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A PXR polymorphism (PXR63396 C>T) influences unboosted atazanavir clearance 
through an effect on hepatic PXR expression and therefore expression of its target 
genes (e.g. CYP3A4, ABCB1and SLCO1B1), which are known to be involved in 
atazanavir clearance (Schipani et al., 2010). PXR haplotype constitution could be 
important in influencing interindividual and interethnic variations in disposition of its 
putative drug substrates through reduced hepatic mRNA expression of PXR and its 
downstream targets (Sandanaraj et al., 2008). PXR and CAR polymorphisms regulate 
the expression of OATP1B (OATP1B1 and OATP1B3) transporters both in vitro and 
in vivo (Meyer zu Schwabedissen et al., 2009).  
 
The aim of this chapter was to investigate the relationship between nuclear receptors 
(PXR and CAR) gene expression and the expression of ABC transporters (ABCB1, 
ABCC1, ABCC2 and ABCC10) and OATP transporters (OATP1A2, OATP1B1, 
OATP1B3, OATP1C1, OATP2A1, OATP2B1, OATP3A1, OATP4A1, OATP4C1, 
OATP5A1 and OATP6A1) in human intestine. The effect of nuclear receptor 
polymorphism (PXR44477 T>C [rs1523130], PXR63396 C>T [rs2472677], 
PXR69789 A>G [rs7643645] and CAR540 C>T [rs2307424]) on the gene expression 
of these ABC transporters and OATP transporters was also determined. 
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2.2 METHODS 
2.2.1 Materials 
TRIzol reagent, chloroform and nuclease free water were purchased from 
Sigma-Aldrich (Poole, UK). Isopropyl alcohol and ethanol were obtained from Fisher 
Scientific (Loughborough, UK). TaqMan reverse transcription (RT) kits were 
purchased from Applied Biosystems (Warrington, UK). Primers and probes for 
real-time PCR based gene expression assay and allelic discrimination assay were 
obtained from Assays by Design Service, Applied Biosystems (Warrington, UK). 
qPCR master mix was obtained from ABgene (Epsom, UK). Whole blood DNA 
extraction kit purchased from QIAGEN (West Sussex, UK). 
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2.2.2 Patients Data 
84 patients were recruited from the Royal Liverpool University Hospital. Patient 
characteristics, including sex, age and ethnicity, were obtained from medical records. 
The group comprised 47 male and 36 female patients (one person no record). The 
average age was 60.3 years old with a range of 17 to 88 years old. The ethnicity of 
these patients included White British, African and others. The intestinal biopsy 
samples from duodenum were used to investigate the human gene expression and the 
matched blood samples were used for genotype. Insufficient biopsy material was 
available to quantify protein expression. 
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2.2.3 Extraction and preparation of mRNA samples 
The D2 intestinal biopsy samples were homogenized in 1ml of Trizol reagent per 
50-100mg of tissue by using a glass-Teflon homogenizer. The sample volume did not 
exceed 10% of the volume of Trizol reagent used for homogenization. 
 
Homogenized tissue samples were incubated for 5 minutes at 37°C to permit the 
complete dissociation of nucleoprotein complexes. 0.2ml of chloroform per ml of Tri 
reagent was added. Sample tubes were shaken vigorously for 15 seconds and 
incubated at 37°C for 2 minutes. Samples were centrifuged at 12,000×g for 15 
minutes at 4°C. The aqueous phase containing total RNA was transferred to a fresh 
tube. RNA was precipitated by mixing with 0.5ml of isopropyl alcohol per ml of Tri 
reagent used. The samples were incubated at 37°C for 10 minutes and RNA harvested 
by centrifugation at 12,000×g for 10 minutes at 4°C. RNA was washed with 75% 
ethanol. RNA pellets were briefly air dried. Then dissolved in 10µl nuclease free 
water and stored at -80°C. 
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2.2.4 Reverse Transcription of mRNA samples 
RNA sample concentration and purity were assessed by spectrophotometry 
(NanoDrop 100 Spectrophotometer, Thermo Scientific, Wilmington, USA). cDNA 
was generated form mRNA by reverse transcription. Reverse transcription reaction 
contained: 10×TaqMan RT buffer (5µl), 25mM MgCl2 (11µl, final conc. 5.5mM), 
dNTP mix (10µl, 500μM each), Random Hexamers (2.5µl), RNase inhibitor (1µl, 
0.4U/μl), Reverse Transcriptase (1.75µl, 1.25U/µl) and RNA (2µg). Reaction 
mixtures were made up to 50μl with RNase free water. Reverse transcription reaction 
occurred by using the Eppendorf Mastercycler gradient, 120V (Eppendorf, Hamburg, 
Germany) 
 
Thermal cycling conditions consisted of 10 minutes at 25°C followed by 30 minutes 
at 48°C and 5 minutes at 95°C with a hold stage on completion at 4°C. The resulting 
cDNA was frozen at -20°C until use. 
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2.2.5 Analysis of mRNA expression by real-time qPCR 
Following reverse transcription cDNA samples were prepared for real-time qPCR as 
follows; cDNA (40ng) was combined with qPCR master mix (4µM), sense and 
antisense primers and oligonucleotide probe mix (0.4µM) (Table 2.1). Separate 
reactions were also conducted with primers and probes for glyceraldehyde 
3-phosphate dehydrogenase (GAPDH) as an internal control.  
 
Thermal cycling conditions consisted of 15 minutes at 95°C followed by 50 cycles of 
15 seconds at 95°C and 60°C. Samples were then held at 4°C. Quantification of PCR 
products occurred in real time and was analysed using the Chromo4 Real-Time 
Detection System (MJ Research, INC. Waltham, Massachusetts, USA). Expression 
data were normalised to GAPDH expression using the comparative ΔΔCt method 
consisting of 2 raised to the power of the difference in the Ct between the reference 
gene GAPDH and the test gene. 
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Table 2.1 TaqMan assay IDs for the assays of gene expression 
Gene Symbol TaqMan Assay ID 
PXR Hs00243666_m1 
CAR Hs00901571_m1 
ABCB1 Hs01067802_m1 
ABCC1 Hs00219905_m1 
ABCC2 Hs00166123_m1 
ABCC10 Hs00375716_m1 
OATP1A2 Hs00366488_m1 
OATP1B1 Hs00272374_m1 
OATP1B3 Hs00251986_m1 
OATP1C1 Hs00203184_m1 
OATP2A1 Hs00213714_m1 
OATP2B1 Hs00194554_m1 
OATP3A1 Hs01030353_m1 
OATP4A1 Hs00983994_m1 
OATP4C1 Hs01030663_m1 
OATP5A1 Hs00229597_m1 
OATP6A1 Hs01053821_m1 
GAPDH Hs03929097_g1 
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2.2.6 Extraction of genomic DNA  
20µl QIAGEN protease was pipetted into a sterile eppendorf (1.5ml microtube). 
200µl whole blood and 200µl lysis buffer AL were added. The eppendorfs were then 
pulse-vortexed for 15s. The samples were incubated at 56°C for 10 minutes, 
centrifuged at 6,000×g for 1 minute to remove any drops of sample from the lid. 
200µl 100% ethanol was then added, the samples were pulse-vortexed for 15s and 
centrifuged at 6,000×g for 1 minute to remove any drops of sample from the lid.  
 
All samples were carefully mixed and then transferred to a spin column without 
wetting the rim of the filter and centrifuged at 6,000×g for 1 minute. The filter was 
placed into a clean collection tube. 500µl wash buffer 1 was then added to the spin 
column, again without wetting the rim and was centrifuged at 6,000×g for 1 minute. 
The filter was placed into a clean collection tube.  
 
500µl wash buffer 2 was then added to the spin column (avoiding wetting the rim) 
and the eppendorf was centrifuged at 13,000×g for 3 minutes to dry the membrane 
completely. The filtrate was discarded. If any remnants remain of buffer 2, it can 
inhibit downstream applications, e.g. PCR. In such case, further centrifugation was 
conducted using a clean collection tube to ensure no buffer carry-over. The filter was 
placed into a new sterile eppendorf.  
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50µl elution buffer 3 was then carefully applied to the filter membrane. When 
extracting gDNA from patient samples, cell counts vary widely, hence eluting DNA in 
50µl elution buffer 3 is recommended to ensure sufficient concentrations.  
 
The samples were incubated at room temperature for 3 minutes and centrifuged at 
6,000×g for 1 minute to elute the gDNA. The filter was discarded and the DNA was 
stored at +4°C for up to a month or stored long-term at -20°C. 
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2.2.7 Quantification of gDNA  
25µl stock PicoGreen was diluted in 5ml ddH2O. PicoGreen is light-sensitive so the 
diluted solution was stored in conditions protected from light. In a MJ white 96-well 
plate, 2µl of DNA sample was added to each well and 50µl of the diluted PicoGreen. 
The plate was covered and centrifuged briefly.  
 
A standard curve was performed using DNA solution of known concentration in 
duplicate. DNA standards started at 200ng/µl serially diluted 1 in 2 down to 0ng/µl. A 
no-template control was included so background fluorescence could be taken into 
account. 
 
The gDNA concentration was quantified by real-time PCR. The standard curve was 
found to follow a linear relationship (Y = 0.221X + 0.0894, R
2
 = 0.9805) between 
concentration and RFU (Figure 2.1). 
 
The average fluorescence was calculated for each standard and used to plot a scatter 
graph (Figure 2.1). There should be 6 standard concentrations used. A straight line of 
best fit was added and using the equation of the line, the DNA concentrations of 
unknown samples were calculated. 
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Figure 2.1 Standard curve showing relationship between concentration and RFU 
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2.2.8 Nuclear receptor polymorphisms genotyping 
Genomic DNA concentrations were normalized to 20ng/μl. Samples were prepared 
for real-time qPCR as follows: 20×Primer mix (1.25μl 1.8μM final concentration), 
20×Probe mix (1.25μl 0.4μM final concentration) 2×qPCR Master Mix (12.5μl) and 
gDNA (2μl) (Table 2.2). Reaction mixtures were then made up to 25μl final volume 
using DNase free water.  
 
Thermal cycling conditions consisted of 15 minutes at 95°C followed by 50 cycles of 
15 seconds at 95°C and 1 minute at 60°C. Samples were then held at 4°C. 
Quantification of PCR products occurred in real-time and was analysed using the 
Chromo4 Real-Time Detection System (MJ Research, INC. Waltham, Massachusetts, 
USA). 
 
Table 2.2 TaqMan assay IDs for the assays of genotype 
SNPs TaqMan Assay ID 
PXR44477 T>C C_9152783_20 
PXR63396 C>T C_26079845_10 
PXR69789 A>G C_1834250_10 
CAR540 C>T C_25746794_20 
 
 
 
 
  CHAPTER 2 
50 
 
2.2.9 Statistical analysis 
The gene expression of drug transporters and nuclear receptors were log10 
transformed and given as median (range) unless stated otherwise. Distribution of the 
gene expression of drug transporters was determined via Shapiro-Wilk test. The 
relationships with gene expression of drug transporters were assessed by 
Mann-Whitney test (for genotype groups) or by simple linear regression (continuous 
data such as the gene expression of nuclear receptors) using Pearson’s rank correlation 
coefficient. Rho is a non-parametric correlation coefficient. A p-value < 0.05 was 
considered to identify groups that were significantly different from each other and a 
p-value < 0.1 was used as a cut off for trend. The genotypes with rare double variants 
(defined by < 3 in the total sample population) were treated as one genotype with the 
heterozygous variants in these analyses. These statistical analyses were conducted 
using Stats Direct (Stats Direct Ltd., Cheshire, UK) 
 
Multivariate analysis was conducted to construct a predictive model using patient 
demographic, nuclear receptor gene expression and genotypes as independent 
variables and the gene expression of drug transporters as the dependent variable. 
Dichotomous variables, including gender, were coded as 0 for female and 1 for male, 
while PXR44477, PXR63396, PXR69789 and CAR540 genotypes were coded as 0, 1 
and 2 for homozygous wild type, heterozygous variants and homozygous variants, 
respectively. Ethnicity was also coded as 0, 1 and 2 for White British, Black African 
and others respectively, while age was included as a continuous variable. Univariate 
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analysis was used to select independent variables with p-values < 0.2 to be included in 
the multivariate analysis. These statistical analysis were conducted using SPSS 20 
(SPSS Inc., Chicago, IL, USA) 
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2.3 RESULTS 
2.3.1 Patient demographics 
84 patients were recruited from the Royal Liverpool University Hospital. Patient 
characteristics, including age, gender and ethnicity, were obtained from medical 
records. The group comprised with 56% males and 43% females (one person no 
record). The average age of patients was 60.3 years old with a range of 17 to 88 years 
old. The ethnicity included 89.3% White British, 3.6% African and 7.2% others (Table 
2.3). 
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Table 2.3 demographics of patient 
Demographics 
Age (yrs) Average 60.3 ± 17.6 
Range 17 to 88 
Gender (n, %) Male 47，56 
Female 36，43 
No record 1, 1 
Ethnicity (n, %) White British 75，89.3 
Black African 3，3.6 
others 6，7.2 
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2.3.2 Correlation of nuclear receptors and ABC transporters expression 
The correlation of gene expression in intestine between nuclear receptors (PXR and 
CAR) and ABC transporters (ABCB1, ABCC1, ABCC2 and ABCC10) were analysed. 
Relationships between PXR & ABCB1 (Rho = 0.46, P < 0.0001), PXR & ABCC1 
(Rho = 0.52, P < 0.0001), PXR & ABCC2 (Rho = 0.52, P < 0.0001) and PXR & 
ABCC10 (Rho = 0.71, P < 0.0001) were evident (Figure 2.2). There were also 
correlations between CAR & ABCB1 (Rho = 0.41, P = 0.0004) and CAR & ABCC2 
(Rho = 0.44, P = 0.0002) (Figure 2.3). 
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(a)                                (b) 
 
(c)                                (d) 
 
Figure 2.2 Correlation of gene expression between PXR and ABC transporters in 
intestine. Correlation between the gene expression of (a) PXR & ABCB1, (b) PXR & 
ABCC1, (c) PXR & ABCC2 and (d) PXR & ABCC10 
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(a)                                 (b) 
 
 (c)                                (d) 
 
Figure 2.3 Correlation of gene expression between CAR and ABC transporters in 
intestine. Correlation between the gene expression of (a) CAR & ABCB1, (b) CAR & 
ABCC1, (c) CAR & ABCC2 and (d) CAR & ABCC10 
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2.3.3 Correlation of nuclear receptors and OATP transporters expression 
Only some biopsy samples had detectable expression of OATP transporters (Table 
2.4). Over 50 % of the intestinal biopsies contained detectable levels of specific 
mRNA for 3 transporters (OATP2B1, 2A1 and 3A1). OATP2B1 was the most 
frequently detected, with 83% of the samples showing expression, with an average 
gene expression of 3.63. OATP2A1 was expressed in 80% of biopsies and had an 
average gene expression of 1.8. For OATP3A1, 60% of biopsy samples expressed it 
with an average gene expression of 3.1. Although the number of detectable samples 
for OATP4A1, OATP4C1 and OATP5A1 was lower than 50%, they were still 
expressed in some biopsy samples. OATP4A1 and OATP5A1 were expressed in 38% 
and OATP4C1 in 46% of the biopsies. The average of their expression was 30.3, 5.9 
and 12.7. However, for the other transporters, less than 1% of the biopsies expressed 
them with no biopsies expressing OATP6A1. From Figure 2.4, it is clear that there is 
high variability in these OATP transporters. In conclusion, OATP2A1, OATP2B1, 
OATP3A1, OATP4A1, OATP4C1 and OATP5A1 are expressed in intestine and there 
was a high variability in these OATP transporters. 
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Therefore, the correlation of gene expression in intestine between nuclear receptors 
(PXR and CAR) and OATP transporters (OATP2A1, OATP2B1, OATP3A1, 
OATP4A1, OATP4C1 and OATP5A1) were analysed. Of particular interest, PXR & 
OATP2A1 (Rho = 0.56, P < 0.0001) and PXR & OATP2B1 (Rho = 0.39, P = 0.001) 
gene expression in intestine were positively correlated (Figure 2.5). Other 
relationships emerged between CAR and OATP4C1 (Rho = 0.40, P = 0.01) (Figure 
2.6). These correlations are summarised in Table 2.5 
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Table 2.4 Detectable expression of OATP transporters in intestine 
Genes 
Samples amount with detectable 
mRNA (%) 
Mean (range) expression (Ct) 
in detectable samples 
OATP1A2 4.9% 1231.3 (0.04, 4921.9) 
OATP1B1 6.2% 0.4 (0.0009, 1) 
OATP1B3 7.4% 0.2 (1.7E-06, 1) 
OATP1C1 3.70% 0.8 (0.1, 1.4) 
OATP2A1 80.2% 1.8 (0.01, 45.6) 
OATP2B1 82.7% 3.6 (0.008, 186.1) 
OATP3A1 60.5% 3.1 (0.09, 64.4) 
OATP4A1 38.3% 30.3 (0.5, 823.1) 
OATP4C1 46.9% 12.7 (0.4, 123.6) 
OATP5A1 38.3% 5.9 (0.4, 84.4) 
OATP6A1 0 0 
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Figure 2.4 Gene expressions of OATP transporters in intestine 
 
 
 
 
 
 
 
 
 
 
 
1A2 1B1 1B3 1C1 2A1 2B1 3A1 4A1 4C1 5A1 6A1
-6
-4
-2
0
2
4
OATP Genes
O
A
T
P
 g
e
n
e
 e
x
p
re
s
s
io
n
  CHAPTER 2 
61 
 
(a)                                                          
 
(b) 
 
Figure 2.5 Correlation of gene expression between PXR and OATP transporters 
in intestine. Correlation between the gene expression of (a) PXR & OATP2A1 and (b) 
PXR & OATP2B1 
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Figure 2.6 Correlation of gene expression between CAR and OATP transporters 
in intestine. Correlation between the gene expression of CAR and OATP4C1 
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Table 2.5 Correlation of gene expression between nuclear receptors and OATP 
transporters in intestine 
 
GENES 
PXR CAR 
P value Rho P value Rho 
OATP2A1 < 0.0001 0.56 0.39 0.11 
OATP2B1 0.001 0.39 0.85 0.02 
OATP3A1 0.12 0.22 0.06 0.27 
OATP4A1 0.49 0.13 0.59 0.10 
OATP4C1 0.10 0.27 0.01 0.40 
OATP5A1 0.73 0.06 0.28 -0.20 
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2.3.4 Allele frequencies for PXR and CAR polymorphisms 
Three PXR polymorphisms (PXR44477, PXR69789 and PXR63396) and one CAR 
(CAR540) polymorphism were investigated in the 84 patients. Allele frequencies for 
the PXR44477 polymorphism were 0.51 for the C allele and 0.49 for the T allele 
(Table 2.6). The allele frequencies for PXR63396 polymorphism were 0.52 for the T 
allele and 0.48 for the C allele (Table 2.6). The PXR69789 polymorphism allele 
frequencies were 0.40 for G allele and 0.60 for the A allele (Table 2.6). The CAR540 
polymorphism was found at a frequency of 0.34 for the T allele and 0.66 for the C 
allele (Table 2.6). The observed genotype frequency was in Hardy-Weinberg 
equilibrium. 
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Table 2.6 Frequencies of PXR and CAR polymorphisms 
SNPs Genotype Frequency n (%) Allele Frequency % 
PXR44477 
T>C  
CC CT TT C T 
22 (28.2) 36 (46.2) 20 (25.6) 51.3 48.7 
PXR63396 
C>T 
TT CT CC T C 
20 (25.6) 41 (52.6) 17 (21.8) 51.9 48.1 
PXR69789 
A>G 
GG GA AA G A 
12 (15.4) 39 (50.0) 27 (34.6) 40.4 59.6 
CAR540 
C>T 
TT CT CC T C 
8 (10.3) 37 (47.4) 33 (42.3) 34.0 66.0 
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2.3.5 Impact of nuclear receptor SNPs on drug transporters expression 
2.3.5.1 Impact of PXR44477 SNP on drug transporters expression 
There was a significant association between PXR44477 polymorphism and ABCC10 
gene expression (P = 0.021) in intestine (Figure 2.7). No significant association was 
found between PXR44477 polymorphism and gene expression of other ABC 
transporters (ABCB1, ABCC1 and ABCC2) and OATP transporters (OATP2A1, 
OATP2B1, OATP3A1, OATP4A1, OATP4C1 and OATP5A1) in intestine (Figure 
2.7). 
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Figure 2.7 Impact of PXR44477 SNP on drug transporters expression. The lines 
indicate the median values. 
 
  CHAPTER 2 
68 
 
2.3.5.2 Impact of PXR63396 SNP on drug transporters expression 
PXR63396 polymorphism was associated with ABCB1 gene expression (P = 0.0496) 
and ABCC2 gene expression (P = 0.023) in intestine (Figure 2.8). No other significant 
associations were found between PXR63396 polymorphism and gene expression of 
ABC transporters (ABCC1 and ABCC10) and OATP transporters (OATP2A1, 
OATP2B1, OATP3A1, OATP4A1, OATP4C1 and OATP5A1) in intestine (Figure 
2.8).  
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Figure 2.8 Impact of PXR63396 SNP on drug transporters expression. The lines 
indicate the median values. 
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2.3.5.3 Impact of PXR69789 SNP on drug transporters expression 
No significant associations were found between PXR69789 polymorphism and gene 
expression of ABC transporters (ABCB1 and ABCC1) and OATP transporters 
(OATP2A1, OATP2B1, OATP3A1, OATP4A1, OATP4C1 and OATP5A1) in intestine 
(Figure 2.9). 
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Figure 2.9 Impact of PXR69789 SNP on drug transporters expression. The lines 
indicate the median values. 
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2.3.5.4 Impact of CAR540 on drug transporters expression 
There were no significant associations between CAR540 polymorphism and gene 
expression of ABC transporters (ABCB1, ABCC1, ABCC2 and ABCC10) or OATP 
transporters (OATP2A1, OATP2B1, OATP3A1, OATP4A1, OATP4C1 and OATP5A1) 
in intestine (Figure 2.10). 
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Figure 2.10 Impact of CAR540 on drug transporters expression. The lines indicate 
the median values. 
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2.3.6 Multivariate analysis of drug transporters expression  
2.3.6.1 Patient characteristics and nuclear receptor expression 
Using multiple linear regression, associations between the expression of drug 
transporters with patient characteristics including age, gender, ethnicity and nuclear 
receptor (PXR and CAR) gene expression in intestine were analysed and are 
summarised in Table 2.7 and 2.8. In univariate analysis, the gene expression of 
ABCB1, ABCC1, ABCC2, OATP2A1, OATP2B1 and OATP4A1 were significantly 
associated with PXR gene expression. Meanwhile, the gene expression of these 
transporters (except ABCC2) also had a significant association with PXR gene 
expression in multivariate analysis. However, a trend towards association was found 
between ABCC2 and PXR gene expression in multivariate analysis.  
 
 
 
 
 
 
 
 
 
 
 
  CHAPTER 2 
75 
 
Table 2.7 Univariate and multivariate linear regression analysis of ABC 
transporters gene expression with patient characteristics and nuclear receptor 
gene expressions 
 
Covariate 
ABCB1 gene expression 
Univariate 
ABCB1 gene expression 
Multivariate 
β P β P 
Age 
451 
(-741 to 1644) 
0.45 - - 
Gender 
17356 
(-23487 to 58199) 
0.40 - - 
Ethnicity 
-5339 
(-50101 to 39423) 
0.81 - - 
CAR gene 
expression 
-1 
(-15 to 13) 
0.88 - - 
PXR gene 
expression 
25717 
(19322 to 32113) 
1.4x10
-11
 
25717 
(19322 to 32113) 
1.4x10
-11
 
Covariate 
ABCC1 gene expression 
Univariate 
ABCC1 gene expression 
Multivariate 
β P β P 
Age 
0.081 
(-1 to 1) 
0.88 - - 
Gender 
-29 
(-66 to 8) 
0.13 
-24 
(-59 to 10) 
0.17 
Ethnicity 
-7 
(-49 to 34) 
0.72 - - 
CAR gene 
expression 
-0.001 
(-0.015 to 0.012) 
0.83 - - 
PXR gene 
expression 
14 
(7 to 22) 
0.0003 
13 
(6 to 21) 
0.0004 
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Table 2.8 Univariate and multivariate linear regression analysis of OATP 
transporters gene expression with patient characteristics and nuclear receptor 
gene expressions 
 
Covariate 
OATP2A1 gene expression 
Univariate 
OATP2A1 gene expression 
Multivariate 
β P β P 
Age 
0.06 
(-0.02 to 0.1) 
0.14 
0.03 
(-0.03 to 0.09) 
0.34 
Gender 
-1.2 
(-3.7 to 1.4) 
0.37 - - 
Ethnicity 
-0.5 
(-3.3 to 2.3) 
0.73 - - 
CAR gene 
expression 
-0.00008 
(-0.001 to 0.001) 
0.86 - - 
PXR gene 
expression 
1.4 
(1.0 to 1.9) 
6.8x10
-9
 
1.4 
(0.1 to 1.9) 
1.6x10
-8
 
Covariate 
OATP2B1 gene expression 
Univariate 
OATP2B1 gene expression 
Multivariate 
β P β P 
Age 
0.081 
(-1 to 1) 
0.88 - - 
Gender 
-29 
(-66 to 8) 
0.13 
-24 
(-59 to 10) 
0.17 
Ethnicity 
-7 
(-49 to 34) 
0.72 - - 
CAR gene 
expression 
-0.001 
(-0.015 to 0.012) 
0.83 - - 
PXR gene 
expression 
14 
(7 to 22) 
0.0003 
13 
(6 to 21) 
0.0004 
Covariate 
OATP4A1 gene expression 
Univariate 
OATP4A1 gene expression 
Multivariate 
β P β P 
Age 
0.002 
(-0.01 to 0.02) 
0.77 - - 
Gender 
-0.08 
(-0.5 to 0.4) 
0.75 - - 
Ethnicity 
-0.2 
(-0.7 to 0.3) 
0.53 - - 
CAR gene 
expression 
-0.00004 
(-0.0002 to 0.0001) 
0.58 - - 
PXR gene 
expression 
0.2 
(0.09 to 0.3) 
0.0002 
0.2 
(0.09 to 0.3) 
0.0002 
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2.3.6.2 Patient characteristics and nuclear receptor polymorphisms 
Associations between the gene expression of drug transporters with patient 
characteristics and nuclear receptor polymorphisms in intestine were analysed by 
using multiple linear regression, which are summarised in Table 2.9 and 2.10. ABCC1 
gene expression had a trend towards association with CAR540 polymorphism in 
univariate analysis, while it was also significant associated with CAR540 
polymorphism in multivariate analysis (Table 2.9). OATP2A1 gene expression was 
significantly associated with CAR540 polymorphism in both univariate and 
multivariate analysis (Table 2.10). OATP3A1 gene expression was found to be 
significantly associated in univariate analysis and a trend towards association in 
multivariate analysis with PXR69789 polymorphism. In univariate analysis, 
OATP4C1 gene expression had a trend towards association with PXR44477 
polymorphism, while it not only had a significant association with PXR44477 
polymorphism but also a trend towards association with patients’ age in multivariate 
analysis (Table 2.10). A trend towards association was observed between OATP5A1 
gene expression and PXR69789 polymorphism in both univariate and multivariate 
analysis (Table 2.10).  
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Table 2.9 Univariate and multivariate linear regression analysis of ABCC1 gene 
expression with patient characteristics and nuclear receptor polymorphisms 
 
Covariate 
ABCC1 gene expression 
Univariate 
ABCC1 gene expression 
Multivariate 
β P β P 
Age -0.08 (-1 to 1) 0.88 -29 (-66 to 7) 0.12 
Gender -29 (-66 to 8) 0.13 - - 
Ethnicity -7 (-49 to 34) 0.72 - - 
CAR540 28 (-0.4 to 56) 0.053 28 (0.04 to 56) 0.0497 
PXR44477 5 (-21 to 31) 0.72 - - 
PXR63396 -7 (-35 to 21) 0.62 - - 
PXR69789 10 (-18 to 37) 0.49 - - 
 
 
 
 
 
 
 
 
 
 
 
 
  CHAPTER 2 
79 
 
Table 2.10 Univariate and multivariate linear regression analysis of OATP 
transporters gene expression with patient characteristics and nuclear receptor 
polymorphisms 
 
Covariate 
OATP2A1 gene expression 
Univariate 
OATP2A1 gene expression 
Multivariate 
β P β P 
Age 0.06 (-0.02 to 0.1) 0.14 0.05 (-0.02 to 0.1) 0.17 
Gender -1 (-4 to 1) 0.37 - - 
Ethnicity -0.5 (-3 to 2) 0.73 - - 
CAR540 2 (0.2 to 4) 0.03 2 (0.1 to 4) 0.04 
PXR44477 1 (-0.7 to 3) 0.25 - - 
PXR63396 -1 (-3 to 0.8) 0.26 - - 
PXR69789 0.07 (-2 to 2) 0.94 - - 
Covariate 
OATP4C1 gene expression 
Univariate 
OATP4C1 gene expression 
Multivariate 
β P β P 
Age -0.2 (-0.5 to 0.08) 0.16 -0.3 (-0.5 to 0.03) 0.07 
Gender -3 (-13 to 7) 0.52 - - 
Ethnicity -1 (-12 to 10) 0.85 - - 
CAR540 -1 (-9 to 6) 0.72 - - 
PXR44477 -6 (-13 to 0.3) 0.06 -7 (-14 to -0.7) 0.03 
PXR63396 2 (-5 to 9) 0.58 - - 
PXR69789 -2 (-9 to 5) 0.54 - - 
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2.4 DISCUSSION 
Nuclear receptors are recognised to be involved in the transcriptional regulation of 
ABC transporters and OATP transporters. In 2005, Albermann et al. found all 
transporters including ABCB1, ABCC1 and ABCC2 had a positive correlation with 
PXR expression in PBMCs and intestine (except ABCC1 in the intestine) but no 
relationship between PXR expression and the expression of ABCB1, ABCC1 and 
ABCC2 in liver (Albermann et al., 2005). In addition, PXR and CAR increased the 
ABCB1 transcription and ABCC2 was also regulated by PXR in human intestinal 
epithelial cells (Haslam et al., 2008). Recently, Jeannesson et al showed the 
expression of ABCB1 and PXR were not significantly correlated in PBMCs 
(Jeannesson et al., 2011). In this study, we found a positive correlation between PXR 
expression and the expression of ABCB1, ABCC1, ABCC2 and ABCC10 in intestine. 
However, the data for ABCC1 is not in agreement with the previous study 
(Albermann et al., 2005). Our data also show correlations of expression between CAR 
and these ABC transporters (except ABCC1) in intestine. These data agree with the 
ABCB1 study of Haslam et al in intestine. We also extended this analysis to ABCC10, 
and relationships were also found between PXR and CAR gene expression with 
ABCC10 gene expression in intestine.  
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Our data show that OATP2A1, OATP2B1, OATP3A1, OATP4A1, OATP4C1, and 
OATP5A1 transporters are expressed in intestine. However, there is a high variability 
in these OATP transporters. Part of the reason for this variability may be the precise 
location of the intestine from which the biopsies were taken. Nevertheless, it is likely 
that pharmacogenetic and/or environmental factors also contribute to this variability. 
In the literature, OATPs are expressed in various cells and tissues, some members 
show a more restricted pattern (well-studied OATP1B1/OATP1B3 in liver, OATP4C1 
in kidney, and OATP6A1 in testis) (Svoboda et al., 2011). Only OATP2B1 has been 
found to be expressed in the intestine and this is in agreement with our data (Visentin 
et al., 2011). However, in contrast to our results, previous studies have shown that 
OATP1A2 is expressed in the intestine (Tamai, 2011). There were significant 
relationships between the expression of CAR with OATP3A1 and CAR with 
OATP4C1 in intestine. Also, it is likely that PXR expression is associated with the 
gene expression of OATP2A1 and OATP2B1. 
 
This chapter also investigated associations between nuclear receptor (PXR and CAR) 
polymorphisms and the gene expression of drug transporters. A statistically significant 
association emerged between PXR63396 polymorphism and the expression of ABCB1 
and ABCC2 in intestine, while PXR44477 polymorphism was associated with 
ABCC10 expression in intestine. PXR63396 alters PXR expression and CYP3A4 
activity in vitro and there is an association of PXR63396 polymorphism with reduced 
concentrations of unboosted Atazanavir (Schipani et al., 2010). PXR (rs2276707) 
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polymorphism was weakly associated with ulcerative colitis susceptibility (Glas et al., 
2011) and PXR25385 (C>T) polymorphism was identified as a significant covariate 
for apparent oral clearance of tacrolimus (Benkali et al., 2009). PXR promoter and 
intron 1 SNPs associated with PXR target gene expression (CYP3A4) in donor livers 
and cultured hepatocytes has also been reported (Lamba et al., 2008). 
 
Multivariate linear regression analysis revealed that PXR expression appeared to be 
involved in the expression of ABC transporters (ABCB1, ABCC1 and ABCC2) and 
OATP transporters (OATP2A1, OATP2B1 and OATP4A1). PXR gene expression 
significantly influenced the gene expression of ABCB1, ABCC1, ABCC2, OATP2A1, 
OATP2B1 and OATP4A1. CAR polymorphism significantly affected the gene 
expression of ABCC1 and OATP2A1, while PXR69789 polymorphism had a trend to 
associate with OATP3A1 and OATP5A1 gene expression. In addition, OATP4C1 was 
significantly influenced by PXR44477 polymorphism and had a trend to associate 
with the age of patients. 
 
In summary we have shown the impact of nuclear receptor gene expression on the 
expression of drug influx and efflux transporters. Also, this chapter describes novel 
associations between nuclear receptor polymorphisms and drug transporter gene 
expression. 
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3.1 INTRODUCTION 
In chapter 2, we investigated the impact of PXR and CAR in the expression of ABC 
transporters which play an important role on influencing the pharmacokinetics of 
orally dosed drugs (Fromm, 2000; Landowski et al., 2003; Mizuno et al., 2002). 
However, enzymes such as Cytochrome P450 are also involved in drug metabolism 
and bioactivation (Wang et al., 2010). Previous study showed that transporter and 
enzyme played complementary roles in drug absorption, distribution, metabolism and 
excretion by biotransformation and counter-transport, particularly in the intestine 
(Benet, 2009). Literature evidence indicates that the positive correlation between PXR 
and ABC transporters in intestine is reversed in liver – this would be consistent with 
enabling increased hepatic residence time and increased metabolism in liver，and in 
intestine increased presentation of drug to CYP3A4 and more metabolisms as a result 
of cycles of efflux. Due to increase ABC transporter expression in intestine, there is 
no need to change CYP3A4 expression level.  
 
In this study, we focus on impact of nuclear receptors (PXR and CAR) on the 
expression of Cytochrome P450 enzymes including CYP2B6 and CYP3A4 in 
intestine. In literature, the human nuclear receptors PXR and CAR are known to 
regulate gene expression of the Cytochrome P450 enzymes, especially, CYP2B6 and 
CYP3A4 (Rhodes et al., 2011). CAR and PXR expression correlate with CYP2B6 
gene expression in liver (Chang et al., 2003). The mRNA expression of CYP3A is 
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also regulated by several nuclear receptors such as PXR and CAR (Hasegawa et al., 
2010).  
 
A number of pharmacological factors influence drug metabolism, including genetic 
variability in metabolizing enzymes and their regulators which possess the capacity to 
modulate enzyme activity and/or expression. These factors become particularly 
important when complex drug regimens are used as is the case in HIV treatment. The 
CYP2B6 polymorphisms are associated with altered hepatic CYP2B6 expression and 
activity (Wyen et al., 2011). CYP2B6 genotype influences plasma efavirenz and 
nevirapine concentrations (Uttayamakul et al., 2010). However, in other studies, 
CYP2B6 polymorphisms were associated with high plasma efavirenz concentrations 
but not nevirapine, while CYP3A4 polymorphisms had no significant impact on 
plasma efavirenz or nevirapine concentrations in a Chinese patient population (Chen 
et al., 2010).  
 
As PXR regulates Cytochrome P450 enzymes, the PXR polymorphisms have revealed 
not only changes in PXR expression and activity, but also effects on CYP3A4 gene 
expression (Svard et al., 2010). PXR polymorphism was associated with significantly 
lower expression of CYP3A4 in liver tissues (Sandanaraj et al., 2008). Furthermore, 
in antiretroviral therapy, several drugs including darunavir, fosamprenavir, lopinavir, 
nelfinavir, tipranavir, efavirenz, and abacavir increased the expression of Cytochrome 
P450 enzymes through PXR (Svard et al., 2010).  
  CHAPTER 3 
87 
 
Chapter 2 detailed the impact of nuclear receptor expression and single nucleotide 
polymorphism on drug transporters in intestine. The aim of this chapter was to 
investigate the correlation between the expression of nuclear receptor (PXR and CAR) 
and Cytochrome P450 enzymes (CYP2B6 and CYP3A4) in intestine. The impact of 
single nucleotide polymorphism of PXR (PXR44477 T>C [rs1523130], PXR63396 
C>T [rs2472677] and PXR69789 A>G [rs7643645]), CAR (CAR540 C>T 
[rs2307424]), CYP2B6 (CYP2B6 516 G>T [rs3745274] and CYP2B6 1459 C>T 
[rs3211371]) and CYP3A4 (CYP3A4 392 A>G [rs2740574]) on the gene expression 
of Cytochrome P450 enzymes in intestine was also investigated.  
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3.2 METHODS 
3.2.1 Materials 
TRIzol reagent, chloroform and nuclease free water were purchased from 
Sigma-Aldrich (Poole, UK). Isopropyl alcohol and ethanol were obtained from Fisher 
Scientific (Loughborough, UK). TaqMan reverse transcription (RT) kits were 
purchased from Applied Biosystems (Warrington, UK). Primers and probes for 
real-time PCR based gene expression assay and allelic discrimination assay were 
obtained from Applied Biosystems (Warrington, UK). qPCR master mix was obtained 
from ABgene (Epsom, UK). Whole blood DNA extraction kit purchased from 
QIAGEN (West Sussex, UK). 
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3.2.2 Patients Data 
84 patients were recruited from the Royal Liverpool University Hospital. Patient 
characteristics, including sex, age and ethnicity, were obtained from medical records. 
The group comprised 47 male and 36 female patients (one person no record). The 
average age was 60.3 years old with a range of 17 to 88 years old. The ethnicity of 
these patients included White British, African and others. The intestinal biopsy 
samples from duodenum were used to investigate the human gene expression and the 
matched blood samples were used for genotype. Insufficient biopsy material was 
available to quantify protein expression. 
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3.2.3 Extraction and Reverse Transcription of mRNA 
The mRNA samples were extracted according to the manufacturer’s instructions as 
outlined in section 2.2.3. The cDNA samples were generated form mRNA by reverse 
transcription according to section 2.2.4. The cDNA concentrations were normalised to 
20ng/μl. 
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3.2.4 Analysis of mRNA by real-time qPCR  
Following reverse transcription cDNA samples were prepared for real-time qPCR as 
follows; cDNA (40ng) was combined with qPCR master mix (4µM), sense and 
antisense primers and oligonucleotide probe mix (0.4µM) (Table 3.1). Separate 
reactions were also conducted with primers and probes for glyceraldehyde 
3-phosphate dehydrogenase (GAPDH) as an internal control.  
 
Thermal cycling conditions consisted of 15 minutes at 95°C followed by 50 cycles of 
15 seconds at 95°C and 60°C. Samples were then held at 4°C. Quantification of PCR 
products occurred in real time and was analysed using the Chromo4 Real-Time 
Detection System (MJ Research, INC. Waltham, Massachusetts, USA). Expression 
data were normalised to GAPDH expression using the comparative ΔΔCt method 
consisting of 2 raised to the power of the difference in the Ct between the reference 
GAPDH and the test gene. 
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Table 3.1 TaqMan assay IDs for the assays of gene expression 
Genes TaqMan Assay ID 
PXR Hs00243666_m1 
CAR Hs00901571_m1 
CYP2B6 Hs03044636_m1 
CYP3A4 Hs00430021_m1 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  CHAPTER 3 
93 
 
3.2.5 Extraction of genomic DNA 
Genomic DNA was extracted according to the manufacturer’s instruction as outlined 
in section 2.2.6. Genomic DNA concentrations were normalised to 20ng/μl. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  CHAPTER 3 
94 
 
3.2.6 Nuclear receptors and cytochrome P450 genotyping 
The gDNA samples were prepared for real-time qPCR as follows: 20×Primer mix 
(1.25μl 1.8μM final concentration), 20×Probe mix (1.25μl 0.4μM final concentration) 
2×qPCR Master Mix (12.5μl) and gDNA (2μl) (Table 3.2). Reaction mixtures were 
then made up to 25μl final volume using DNase free water.  
 
Thermal cycling conditions consisted of 15 minutes at 95°C followed by 50 cycles of 
15 seconds at 95°C and 1 minute at 60°C. Samples were then held at 4°C. 
Quantification of PCR products occurred in real-time and was analysed using the 
Chromo4 Real-Time Detection System (MJ Research, INC. Waltham, Massachusetts, 
USA). 
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Table 3.2 TaqMan assay IDs and primer-probe sequences for the assays of 
genotype 
 
SNPs TaqMan Assay ID 
PXR44477 T>C C_26079845_10 
PXR63396 C>T C_9152783_20 
PXR69789 A>G C_1834250_10 
CAR540 C>T C_25746794_20 
 Primer-probe sequences 
CYP2B6 516 G>T Forward: CTTGACCTGCTGCTTCTTCCTA 
Reverse: AGACGATGGAGCAGATGATGTTG 
FAM: TTCCATTCCATTACCG 
VIC: TTCCAGTCCATTACCG 
CYP2B6 1459 C>T Forward: CCACACTGGTGACCTTCTGT 
Reverse: CTTCCCTCAGCCCCTTCAG 
FAM: AGGAAGCAGATCTG 
VIC: AGGAAGCGGATCTG 
CYP3A4 392 A>G Forward: AGTGGAGCCATTGGCATAAAATCT  
Reverse: TGGAATGAGGACAGCCATAGAGA 
FAM: AAGGGCAAGAGAGAG  
VIC: CAAGGGCAGGAGAGAG    
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3.2.7 Statistical analysis 
The gene expression of cytochrome P450 and nuclear receptors were log10 
transformed and given as median (range) unless stated otherwise. Distribution of the 
gene expression of cytochrome P450 was determined via Shapiro-Wilk test. The 
effects on the gene expression of cytochrome P450 were assessed by Mann-Whitney 
test (for genotype groups) or by simple linear regression (continuous data such as the 
gene expression of nuclear receptors) using Pearson’s rank correlation coefficient. 
Rho is a non-parametric correlation coefficient. A p-value < 0.05 was considered to 
identify groups that were significantly different from each other and a p-value < 0.1 
was used as a cut off for trend. The genotypes with rare double variants (defined by < 
3 in the total sample population) were treated as one genotype with the heterozygous 
variants in these analyses. These statistical analyses were conducted using Stats Direct 
(Stats Direct Ltd., Cheshire, UK) 
 
Multivariate analysis was conducted to construct a predictive model using patient 
demographic, nuclear receptor gene expression and genotypes as independent 
variables and the gene expression of cytochrome P450 as the dependent variable. 
Dichotomous variables, including gender, were coded as 0 for female and 1 for male, 
while PXR44477, PXR63396, PXR69789, CAR C>T (rs2307424), CYP2B6 G516T, 
CYP2B6 C1459T and CYP3A4 A392G genotypes were coded as 0, 1 and 2 for 
homozygous wild type, heterozygous variants and homozygous variants, respectively. 
Ethnicity was also coded as 0, 1 and 2 for White British, Black African and others 
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respectively, while age was included as a continuous variable. Univariate analysis was 
used to select independent variables with p-values < 0.2 to be included in the 
multivariate analysis. These statistical analysis were conducted using SPSS 20 (SPSS 
Inc., Chicago, IL, USA) 
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3.3 RESULTS 
3.3.1 Patient demographics 
84 patients were recruited from the Royal Liverpool University Hospital. Patient 
characteristics, including age, gender and ethnicity, were obtained from medical 
records. The group comprised with 56% males and 43% females (one person no 
record). The average age of patients was 60.3 years old with a range from 17 to 88 
years old. The ethnicity included 89.3% White British, 3.6% African and 7.2% others 
(Table 3.3). 
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Table 3.3 demographics of patient 
Demographics 
Age (y) Average 60.3 ± 17.6 
Range 17 to 88 
Gender (n, %) Male 47，56 
Female 36，43 
No record 1, 1 
Ethnicity (n, %) White British 75，89.3 
Black African 3，3.6 
others 6，7.2 
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3.3.2 Correlation of nuclear receptor and cytochrome P450 expression 
The correlation of gene expression in intestine between nuclear receptors (PXR and 
CAR) and cytochrome P450 (CYP2B6 and CYP3A4) were analysed. Negative 
correlations of PXR with CYP2B6 (Rho = -0.44, P < 0.0001) and PXR with CYP3A4 
(Rho = -0.61, P < 0.0001) emerged (Figure 3.1). A relationship between CAR and 
CYP3A4 (Rho = -0.51, P < 0.0001) was also evident, while no other significant 
correlations were observed between CAR and CYP2B6 (Figure 3.2). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  CHAPTER 3 
101 
 
(a)  
 
(b) 
 
Figure 3.1 Correlation of gene expression between PXR and cytochrome P450 in 
intestine. Correlation between the gene expression of (a) PXR & CYP2B6 and (b) 
PXR & CYP3A4 
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(a) 
 
(b) 
 
Figure 3.2 Correlation of gene expression between CAR and cytochrome P450 in 
intestine. Correlation between the gene expression of (a) CAR & CYP2B6 and (b) 
CAR & CYP3A4 
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3.3.3 Allele frequencies for PXR, CAR and CYPs polymorphisms 
Three PXR polymorphisms (PXR44477, PXR63396 and PXR69789) and one CAR540 
polymorphism were investigated in the 84 patients. The results were shown in section 
2.3.4. Two CYP2B6 polymorphisms (CYP2B6 G516T and C1459T) were investigated 
in the 84 patients. Allele frequencies for the CYP2B6 G516T polymorphism in 
intestine were 0.74 for the G allele and 0.26 for the T allele (Table 3.4). The CYP2B6 
C1459T polymorphism allele frequencies were 0.83 for the C allele and 0.17 for the T 
allele (Table 3.4). The CYP3A4 A392G polymorphism was found at a frequency of 
0.95 for the A allele and 0.05 for the G allele (Table 3.4). The observed genotype 
frequency was in Hardy-Weinberg equilibrium. 
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Table 3.4 Frequencies of nuclear receptor and cytochrome P450 polymorphisms 
SNPs Genotype Frequency n (%) Allele Frequency % 
CYP2B6 516 
G>T 
TT GT GG T G 
0 (0) 40 (52.6) 36 (47.4) 26.3 73.7 
CYP2B6 1459 
C>T 
TT CT CC T C 
0 (0) 27 (34.6) 51 (65.4) 17.3 82.7 
CYP3A4 392 
A>G 
AA AG GG A G 
72 (92.3) 5 (6.4) 1 (1.3) 95.5 4.5 
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3.3.4 Nuclear receptors polymorphisms and CYPs expression 
There were no significant associations between CAR & PXR (PXR44477, PXR69789 
and PXR63396) polymorphism and gene expression of CYP2B6 and CYP3A4 in 
intestine (Figure 3.3 and 3.4). Similarly, no significant associations were found 
between cytochrome P450 polymorphisms (CYP2B6 G516T, CYP2B6 C1459T and 
CYP3A4 A392G) and gene expression of CYP2B6 or CYP3A4 in intestine (Figure 3.5 
and 3.6). 
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(a) 
 
(b) 
 
Figure 3.3 Expression of cytochrome P450 in intestine according to CAR 
genotypes. Expression of CYP2B6 (a) and CYP3A4 (b) according to CAR genotype 
and the lines indicate the median values. 
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(a) 
 
(b)  
 
(c) 
 
Figure 3.4 Expression of cytochrome P450 in intestines according to PXR 
genotypes. Expression of CYP2B6 and CYP3A4 in intestines according to PXR44477 
genotype (a), PXR63396 genotype (b) and PXR69789 genotype (c) and the lines 
indicate the median values. 
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(a) 
 
(b) 
 
Figure 3.5 Expression of CYP2B6 in intestines according to CYP2B6 genotypes. 
Expression of CYP2B6 according to CYP2B6 G516T genotype (a), and CYP2B6 
C1459T genotype (b) and the lines indicate the median values. 
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Figure 3.6 Expression of CYP3A4 in intestines according to CYP3A4 A392G 
genotypes. The lines indicate the median values. 
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3.3.5 Multivariate analysis of cytochrome P450 gene expression 
3.3.5.1 Patient characteristics and nuclear receptor expression 
Using multiple linear regression, associations of cytochrome P450 (CYP2B6 and 
CYP3A4) gene expression with patient characteristics (age, gender and ethnicity), 
nuclear receptor (PXR and CAR) gene expression were analysed and are summarised 
in Table 3.5. In univariate and multivariate analysis, CYP2B6 and CYP3A4 gene 
expression were not associated with the age, gender, ethnicity, PXR expression or CAR 
gene expression (Table 3.5). 
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Table 3.5 Univariate and multivariate linear regression analysis of cytochrome 
P450 gene expression with patient characteristics and nuclear receptor gene 
expressions 
 
Covariate 
CYP2B6 gene expression 
Univariate 
CYP2B6 gene expression 
Multivariate 
β P β P 
Age -0.3 (-0.7 to 0.2) 0.30 - - 
Gender 2 (-15 to 18) 0.85 - - 
Ethnicity -4 (-22 to 15) 0.70 - - 
CAR expression 
-0.001 
(-0.007 to 0.005) 
0.82 - - 
PXR expression -1 (-5 to 3) 0.55 - - 
Covariate 
CYP3A4 gene expression 
Univariate 
CYP3A4 gene expression 
Multivariate 
β P β P 
Age 0.006 (-0.1 to 0.1) 0.93 - - 
Gender 2 (-3 to 6) 0.46 - - 
Ethnicity -0.7 (-5 to 4) 0.77 - - 
CAR expression 
-0.0002 
(-0.002 to 0.001) 
0.81 - - 
PXR expression -0.5 (-1 to 0.4) 0.27 - - 
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3.3.5.2 Patient characteristics and nuclear receptor polymorphisms 
Associations between the gene expression of cytochrome P450 (CYP2B6 and 
CYP3A4) with patient characteristics and nuclear receptor polymorphisms in intestine 
were analysed by using multiple linear regression, which are summarised in Table 3.6. 
In univariate analysis, CYP3A4 gene expression was significantly associated with 
CAR540 polymorphism and had a trend towards correlation with PXR69789 
polymorphism (Table 3.5). However, there was only a trend towards association 
between CYP3A4 gene expression and CAR polymorphism in multivariate analysis 
(Table 3.5). 
 
 
 
 
 
 
 
 
 
 
 
 
 
  CHAPTER 3 
113 
 
Table 3.6 Univariate and multivariate linear regression analysis of cytochrome 
P450 gene expression with patient characteristics and nuclear receptor 
polymorphisms 
 
Covariate 
CYP2B6 gene expression 
Univariate 
CYP2B6 gene expression 
Multivariate 
β P β P 
Age -0.3 (-0.7 to 0.2) 0.30 - - 
Gender 2 (-15 to 18) 0.85 - - 
Ethnicity -4 (-22 to 15) 0.70 - - 
CAR540 -8 (-21 to 4) 0.19 -9 (-21 to 4) 0.18 
PXR44477 5 (-7 to 16) 0.42 - - 
PXR63396 6 (-7 to 18) 0.36 - - 
PXR69789 -0.03 (-12 to 12) 0.99 - - 
CYP2B6G516T -13 (-29 to 4) 0.12 -13 (-29 to 3) 0.11 
CYP2B6C1459T 7 (-11 to 24) 0.45 - - 
Covariate 
CYP3A4 gene expression 
Univariate 
CYP3A4 gene expression 
Multivariate 
β P β P 
Age 0.006 (-0.1 to 0.1) 0.93 - - 
Gender 2 (-3 to 6) 0.46 - - 
Ethnicity -0.7 (-5 to 4) 0.77 - - 
CAR540 3 (0.1 to 7) 0.043 3 (-0.09 to 7) 0.057 
PXR44477 2 (-0.8 to 5) 0.15 1 (-2 to 4) 0.52 
PXR63396 2 (-0.9 to 5) 0.16 2 (-2 to 5) 0.40 
PXR69789 3 (-0.08 to 6) 0.056 2 (-2 to 6) 0.32 
CYP3A4A392G -1 (-8 to 5) 0.65 - - 
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3.4 DISCUSSION 
Nuclear receptors are transcription factors that regulate the expression of cytochrome 
P450 enzymes. In this study, a negative significant correlation was found between 
PXR and CYP2B6 gene expression in intestine. While a positive and statistically 
significant correlation was been reported between CYP2B6 with CAR and CYP2B6 
with PXR gene expression in liver (Chang et al., 2003). A previous study also showed 
the nuclear receptor (PXR and CAR) gene expression is significantly correlated with 
CYP3A expression in human fetal and pediatric liver (Vyhlidal et al., 2006). A 
positive correlation between hepatic PXR and CYP3A4 gene expression has been 
reported (Lamba et al., 2010). However, our study obtained a negative significant 
correlation between CYP3A4 gene expression and the gene expression of PXR and 
CAR in intestine. The reasons for this difference between liver and intestine require 
for the study but may involve differences between expressions of other transcription 
factors such as Vitamin D between these tissues. In literature, PXR dominantly 
controls CYP3A4 inducibility in the liver, whereas Vitamin D receptor transactivates 
CYP3A4 in the intestine by secondary bile acids (Pavek et al., 2010). 
 
This study also investigated an association between nuclear receptor polymorphisms 
(PXR44477, PXR69789 and PXR63396 and CAR C>T [rs2307424]) and the gene 
expression of cytochrome P450 enzymes (CYP2B6 and CYP3A4) in intestine but no 
statistically significant associations emerged. In the literature, PXR63396 
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polymorphism has been reported to be associated with CYP3A4 gene expression in 
liver which is known to be involved in atazanavir clearance (Schipani et al., 2010). 
Another PXR polymorphism (PXR A566C) was significantly associated with 
CYP3A4 RNA expression in colon tumour (King et al., 2007).  
 
The association between CYP2B6 and CYP3A4 polymorphisms (CYP2B6 G516T, 
CYP2B6 C1459T and CYP3A4 A392G) and the gene expression of cytochrome P450 
enzymes (CYP2B6 and CYP3A4) in intestine was also investigated. No association 
emerged which is different from previous studies. For example, CYP2B6 C1459T 
significantly reduced CYP2B6 protein expression in liver (Lang et al., 2001), while 
CYP3A4 A392G has been shown to be in association with altered CYP3A4 gene 
expression, also in liver (Svard et al., 2010). CYP2B6 G516T has been correlated to 
changes in plasma drug concentrations of efavirenz and nevirapine in patients (Saitoh 
et al., 2008; Svard et al., 2010). CYP2B6 C1459T was also associated with the lowest 
level of CYP2B6 activity in the livers of females (Lamba et al., 2003).  
 
In multivariate linear regression analysis, CAR C>T (rs2307424) polymorphism 
independent significantly influenced the CYP3A4 gene expression, while CYP3A4 
gene expression also had a trend to be associated with PXR69789 polymorphism. The 
patient characteristics including age, gender and ethnicity had no influence on 
CYP2B6 or CYP3A4 gene expression. Similarly, no association between nuclear 
receptor gene expression and CYP2B6 or CYP3A4 gene expression were observed in 
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this analysis. 
 
In summary, the expression of cytochrome P450 enzymes was negatively affected by 
nuclear receptor gene expression in intestine. CYP3A4 expression was significantly 
associated with CAR C>T (rs2307424) polymorphism in univariate analysis but there 
was only a trend towards association in multivariate analysis. Meanwhile, CYP3A4 
expression also had a trend to be associated with PXR69789 polymorphism in 
univariate analysis. No genetic associations with CYP2B6 and CYP3A4 expression 
were observed. Clearly, these data indicate significant differences in regulation of 
CYP2B6 and CYP3A4 in liver/intestinal tumours compared to intestine that are now 
worthy of further study. 
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4.1 INTRODUCTION 
Efavirenz (EFV) is a non-nucleoside reverse transcription inhibitor (NNRTI) and is 
used as part of highly active antiretroviral therapy (HAART) for the treatment of 
HIV-1. It is used in combination with lamivudine/zidovudine (Combivir) or 
tenofovir/emtricitabine (Truvada) as the preferred NNRTI-based regimens in adults 
and adolescents. NNRTIs inhibit the reverse transcriptase enzyme which is an 
essential viral enzyme used to transcribe viral RNA into DNA. NNRTIs do not bind to 
the active site of the polymerase but in a less conserved pocket near the active site. 
Their binding results in a conformational change in the reverse transcriptase that 
distorts the positioning of the residues that bind DNA, inhibiting polymerization (De 
Clercq, 1998). 
 
EFV is metabolized in the liver, and is a substrate and inducer of CYP2B6 and 
possibly CYP3A4 (Asimus et al., 2009; Berruet et al., 2005). Large coefficients of 
variation in plasma levels are observed. For example, EFV intrapatient concentration 
variation is 30% and interpatient variation is 118% (Marzolini et al., 2001). Plasma 
concentrations of the NNRTIs have been shown to correlate with virological response 
(Fabbiani et al., 2009) and the relationship between EFV pharmacokinetics and 
pharmacodynamics has been investigated in numerous clinical studies. In 2001, 
Marzolini et al described an association between EFV plasma exposure with the 
probability of viral suppression and side effects in 130 patients (Marzolini et al., 
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2001). These data have been further expanded in a cohort of 235 patients and a clear 
association between EFV plasma exposure and efficacy was observed (Csajka et al., 
2003). Patients with EFV concentrations below a cut-off of 1000 ng/ml had a much 
higher probability of therapeutic failure compared to patients with higher EFV 
concentrations. Similar observations were found in other clinical studies on 68 
patients (Stahle et al., 2004) and 300 patients (Leth et al., 2006). However, in a more 
recent study of 71 patients (3 of which had therapeutic failure) this was not replicated 
(Josephson et al., 2010). Although we do not have a complete understanding of the 
link between EFV exposure and CNS side effects, several studies have identified an 
association between plasma concentrations and CNS toxicity (Clifford et al., 2005; 
Csajka et al., 2003; Gallego et al., 2004; Gutierrez et al., 2005; Johnson et al., 2011; 
Marzolini et al., 2001; Nanzigu et al., 2011; Nunez et al., 2001; van Luin et al., 2009; 
Wintergerst et al., 2008). 
 
Therapeutic drug monitoring (TDM) is the practice of directly measuring and 
managing plasma drug levels. It represents one approach to addressing uncertain 
concentrations resulting from standard dosing regimens. For antiretroviral therapy in 
HIV disease, it is used particularly for PIs and NNRTIs (Wertheimer et al., 2006). The 
therapeutic drug monitoring of EFV may be used to improve the potency and the 
durability of the drug regimen, to identify patients with sub-optimal adherence and to 
minimise drug toxicity (Katsounas et al., 2007; Maitland et al., 2005). 
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The decision on when to start treatment should take into account CD4 count, HIV 
viral load, co-infections, disease status, treatment history, resistance profiles and 
patient preference. Viral load is the measure of the severity of a viral infection, and 
can be calculated by quantifying the amount of virus in an involved body fluid. 
Tracking viral load is used to monitor therapy during chronic viral infections, such as 
HIV-1, cytomegalovirus, hepatitis B virus, and hepatitis C virus (Nijman et al., 2012; 
Pardo-Yules et al., 2012; Parisi et al., 2012; Tseng et al., 2012). An HIV viral load 
greater than 100,000 copies/ml of blood within six months of seroconversion indicates 
a greater likelihood of developing AIDS within five years (Clinlab-Navigator, 2012). 
Conversely, a viral load less than 10,000 copies/ml in the early stages indicates a 
better prognosis with decreased risk of developing AIDS (Engels et al., 1999).  
 
Successful combination therapy should give a fall in viral load of 1.5 to 2 logs 
(30-100 folds) within six weeks, with the viral load falling below the limit of 
detection within four to six months (AIDSinfo, 2012). The limit of quantification for 
viral load was initially 400 copies/ml with first-generation tests, and later 50 
copies/ml with second-generation tests following the introduction of viral load 
monitoring in clinical practice (Doyle et al., 2012). Extensive evidence from clinical 
trials and observational studies has shown that maintaining a viral load lower than 50 
copies/ml predicts long-term virologic suppression and sustained immunologic and 
clinical benefit (Geretti et al., 2008; Margot et al., 2009; Mocroft et al., 2007). 
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In this study, we investigated the virologic outcomes of treated patients showing a 
viral load lower than 50 copies/ml at an arbitrarily selected time point during HAART 
(time zero, T0VL) according to whether the actual, unreported T0VL result showed a 
level between RNA detected (RNA+) or RNA not detected (RNA-). We also 
investigated the EFV concentration of TOVL plasma samples and compared them as 
two groups (RNA+ and RNA-). The aim of this study was to find the influence 
between patients’ demographics (age, gender and ethnicity) and EFV plasma 
concentrations with the impact of EFV plasma concentration on the T0VL in patients 
receiving HAART. 
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4.2 METHODS 
4.2.1 Materials and Instruments 
Efavirenz (EFV) was donated by DuPont Pharmaceuticals Company (Wilmington, 
USA). Blank plasma was obtain form the National Blood Service. Acetonitrile (ACN), 
Methanol (MeOH), Ethyl acetate [Cat no 152516Q] and n-hexane were purchased 
from VWR International Ltd. (Leicestershire, UK). Potassium carbonate (K2CO3) and 
ammonium acetate were purchased from Sigma Aldrich (Poole, UK). Internal 
standard Ro 31-9564 were purchased from Roche Discovery (Welwyn, UK). 
Deionised water was obtained from the reservoir of the Option 4 water purifier (Elga, 
High Wycombe, Bucks, and UK). The HPLC consisted of a Dionex (Dionex Softron 
GmbH, Germany) HPLC system with a P 680 pump, ASI-100 automated sample 
injector and UVD170U detector. Reversed-phase-liquid chromatography was carried 
out using a Hypurity C18 analytical column, 5μm 150 × 4.6mm from Thermo Electron 
Corporation (Runcorn, UK) with a pre-column guard (Si 60 × 5 mm; Merck, New 
Jersey, USA).  
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4.2.2 Patients Data  
The study population comprised 187 patients from the Royal Free Hospital (Table 
4.3). Patient characteristics, including age, gender and ethnicity, were obtained from 
medical records. The group was comprised of 144 male and 43 female patients. The 
average age of patients was 44.2 years old with a range of 25.4 to 67 years old. The 
ethnicity of these patients included White, Black and others. The patients at an 
arbitrary time point during HAART (T0) showed one of the following VL results: 
RNA+ (n = 91) or RNA- (n = 96). 
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4.2.3 Preparation of Reagents, Standards and Quality Controls 
 Rinsing and Extraction solvent 
Rinsing solvent was composed of deionised water and ACN (50:50 v/v) and 
extraction solvent was composed of ethyl acetate and n-hexane (50:50 v/v). 
 
 Stock Potassium Carbonate Buffer and Ammonium Acetate Buffer  
Stock potassium carbonate buffer (1M) was prepared with 69.1g potassium carbonate 
in 500ml deionised water and ammonium acetate buffer (1M) was prepared with 
38.54g ammonium acetate in 500ml deionised water. Both of them were stored at 
room temperature. 
 
 Mobile Phase 
4ml of 1M ammonium acetate buffer was diluted with 400ml deionised water. 95ml 
methanol was added and then made up to 1000ml with ACN. The mobile phase for 
the analysis was composed of ammonium acetate, ACN and MeOH (400:505:95 v/v) 
and was prepared fresh for each assay. 
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 EFV Stock Standard 
1mg/ml solution of EFV was prepared by weighing out approximately 5mg of drug 
into a 10ml glass tube with the equivalent volume of methanol added. Then 0.8ml of 
this EFV solution was moved into a 100ml flask with blank plasma up to the mark to 
make the 8μg/ml EFV plasma stock solution. 900μl of plasma was moved into the 
0.2ml screw cap micro tubes and stored at -20°C. 
 
 Working Internal Standard  
10mg internal standard (Ro 31-9564) was dissolved in 10ml methanol to prepare the 
stock internal standard (1mg/ml) which was stored at 4°C in a 10ml capped tube. 2.5 
ml of stock internal standard and 7.5ml methanol were used to prepare fresh working 
internal standard (250μg/ml) for each assay. 
 
 Quality Controls (QCs) 
1mg/ml solution of EFV was prepared by weighing out approximately 5mg of drug 
into 10ml glass tube with the appropriate volume of methanol added. Three 50ml 
flasks were labelled with low, medium and high. The correct volume of each drug was 
moved into each flask (Table 4.1). Then bank plasma was added to each flask up to 
the mark. Finally, 500μl of plasma was moved to screw cap micro tubes and stored at 
-20°C. 
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Table 4.1 Quality controls: concentrations and volumes of EFV 
 
Flasks 
EFV 
Concentration (ng/ml) Volume (μl) of 1mg/ml 
Low 800 40 
Medium 4000 200 
High 12000 600 
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4.2.4 Quantification of efavirenz 
Validation of the optimized HPLC method was done with following parameters: 
specificity (UV diode array detector), linearity (three preparations at each of the 80, 
100 and 120% levels), Range (80-120%), Accuracy (three preparations at each level), 
Precision (repeatability studies), detection limit, quantitation limit and stability in 
solution. In this study, EFV plasma levels were determined by the use of reverse 
phase HPLC with UV detection. EFV was extracted from patient plasma samples with 
ethyl acetate and n-hexane. The extract was then dried and reconstituted with the 
mobile phase. Separation was achieved by the relative non polar interactions of the 
components of interest (EFV) with the hydrophobic stationary phase and mobile 
phase. Compounds were separated into individual peaks with more hydrophobic 
analytes being retained longer on the column. Ultra-violet detection was used to 
measure concentration of EFV. Compounds differentially absorb light at a fixed 
wavelength. Absorbance is proportional to the concentration of the analyte. EFV 
concentrations were determined by comparison to a calibrator of known concentration. 
An internal standard solution was included in the sample extraction procedure to 
correct for any variation in extraction efficiency.  
 
The stock EFV, QCs and patient samples were centrifuged at 2000 rpm for 4min. 50μl 
stock EFV was diluted by 450μl blank plasma to prepare a 1:10 diluted stock EFV. 
The correct volume of blank plasma, stock EFV and diluted stock EFV were moved 
into each tube by using the formula in Table 4.2. 200μl QCs (low, medium and high) 
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and patient samples were moved into 7ml glass tube. Internal standard (20μl, 
250μg/ml) was added to plasma samples (200μl) and standards (range 100–8000ng/ml; 
200μl). Potassium carbonate (100μl, 1M) and ethyl acetate/n-hexane (50:50 v/v; 3ml) 
were added to each tube and the samples tumbled for 30 min using a rotary mixer. 
Following centrifugation (4000×g; 5min), the aqueous layer was frozen using a 
cryogenic bath, the organic layer transferred into clean glass tubes and evaporated to 
dryness. Dried extracts were then reconstituted in mobile phase (150μl), vortexed 
thoroughly and transferred into autosampler vials ready for injection (50μl) in the 
HPLC system. Recovery of efavirenz, after extraction from plasma, using this method 
is 98%. Efavirenz and IS were resolved on a Hypurity C18 column with a pre-column 
guard with an HPLC system using the mobile phase (1mM ammonium acetate 
buffer/ACN/methanol; 400:505:95; by vol.) at a flow rate of 1.2 ml/min. The 
ultraviolet detector was set to monitor the 250nm wavelength. Efavirenz and IS eluted 
at 5.3 and 13.5 min, respectively. The peak areas for efavirenz and internal standard 
were quantified using the Chromeleon data acquisition system (Dionex Corporation, 
California, USA). The lower limit of quantification of efavirenz in plasma was taken 
as the lowest point on the standard curves (110ng/ml for the standard curves). 
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Table 4.2 Calibration standards: concentrations and volumes of EFV 
Tube number Concentration 
(ng/ml) 
Diluted stock EFV 
(μl) 
Blank plasma  
(μl) 
1,2 0 0 200 
3,4 100 25 175 
5,6 200 50 150 
7,8 500 125 75 
Tube number Concentration 
(ng/ml) 
Stock EFV 
(μl) 
Blank plasma  
(μl) 
9,10 1000 25 175 
11,12 2000 50 150 
13,14 4000 100 100 
15,16 8000 200 0 
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4.2.5 Statistical analysis  
The plasma concentration of EFV was log10 transformed and given as median (range) 
unless stated otherwise. Distribution of the EFV plasma concentrations was 
determined via Shapiro-Wilk test. The effects of patient demographics and genotypes 
on the EFV plasma concentrations were assessed by Mann-Whitney test (for gender 
and ethnicity) or by simple linear regression (continuous data including age) using 
Pearson’s rank correlation coefficient. The effect of EFV plasma concentration on VL 
was assessed by Mann-Whitney test. Rho is a non-parametric correlation coefficient. 
A p-value < 0.05 was considered to identify groups that were significantly different 
from each other and a p-value < 0.1 was used as a cut off for trend. These statistical 
analysis were conducted using Stats Direct (Stats Direct Ltd., Cheshire, UK) 
 
Multivariate linear regression analysis was conducted to construct a predictive model 
using patient demographic and EFV plasma concentration as independent variables 
and T0VL as dependent variable. Dichotomous variables were coded as 0 for female 
and 1 for male, while ethnicity was coded as 0, 1 and 2 for White, Black and others 
respectively and VL was also coded as 0, 1 and 2 for 40-49 copies/ml, RNA+ and 
RNA-, respectively. Age was included as a continuous variable. Univariate analysis 
was used to select the independent variables with p-values < 0.2 to be included in the 
multivariate analysis. These statistical analysis were conducted using SPSS 20 (SPSS 
Inc., Chicago, IL, USA) 
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4.3 RESULTS 
4.3.1 Study population 
187 patients were recruited from the Royal Free Hospital. Patient characteristics, 
including age, gender and ethnicity, were obtained from medical records. The group 
comprised of 77% males and 23% females. The average age of patients was 44.2 
years old with a range of 25.4 to 67 years old. The ethnicity included 64.2% White, 
29.9% Black and 5.9% others (Table 4.3). The patients at an arbitrary time point 
during HAART (T0) showed 48.7% RNA+ and 51.3% RNA-. The characteristics of 
the study population at T0 are summarised in Table 4.3. 
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Table 4.3 Characteristics of the population at study entry, defined as time zero 
(T0) 
 
Demographics 
Age (y) Average 44.2 
Range 25.4 to 67 
Gender (n, %) Male 144，77.0 
Female 43，23.0 
Ethnicity (n, %) White 120，64.2 
Black 56，29.9 
others 11，5.9 
HIV RNA copies (n, %) RNA+ 91, 48.7 
RNA- 96, 51.3 
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4.3.2 Linearity, limit of quantification and limit of detection 
The lower limit of quantification of EFV was 100.7ng/ml whereas the upper limit of 
quantification was 8137.1ng/ml. The concentration response relationship for EFV 
standard was found to be linear in the concentration range of 100.7ng/ml to 
8137.1ng/ml (Figure 4.1). This linear relationship was demonstrated by coefficient of 
variation obtained from the daily standard curve used for the analysis of unknown 
samples. 
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Figure 4.1 Plots of the calibration curve showing the concentration response 
relationship of EFV standard 
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4.3.3 Impact of patient demographic on EFV plasma concentration 
Patient demographic including age, gender and ethnicity were investigated for their 
influence on EFV plasma concentration at T0. No correlation between age and EFV 
plasma concentration at T0 emerged (Figure 4.2). There were also no significant 
associations between gender and EFV plasma concentration at T0 (Figure 4.3) and no 
relationship was found between ethnicity and EFV plasma concentration at T0 (Figure 
4.4). 
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Figure 4.2 Correlation between age and EFV plasma concentration 
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Figure 4.3 Impact of gender on EFV plasma concentration. The lines indicate the 
median values. 
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Figure 4.4 Impact of ethnicity on EFV plasma concentration. The lines indicate 
the median values. 
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4.3.4 Impact of EFV plasma concentration on VL 
We investigated T0 EFV plasma levels among 187 patients receiving EFV-based 
HAART, comprising 91 patients with detectable HIV-1 RNA+ and 96 patients with 
RNA-. In these two groups, the median EFV levels at T0 were 1341.5ng/ml and 
1729.7ng/ml respectively (p = 0.008). The levels were above the recommended 
threshold of 1000ng/ml in 63/91 (69.2%) and 81/96 (84.4%) patients respectively (p = 
0.25). We also detected a significant difference in EFV plasma concentrations 
between the different T0VL groups (Figure 4.5). 
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Figure 4.5 Efavirenz plasma concentrations at T0 in patients receiving 
Efavirenz-based HAART. The lines indicate the median values. 
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4.3.5 Multivariate analysis  
In univariate analyses, age, gender ethnicity and EFV plasma concentration were not 
significantly correlated with T0VL but gender and ethnicity had a trend towards 
correlation with T0VL. In multivariate analysis, age, gender, ethnicity and EFV plasma 
concentration were not significantly correlated with T0VL as shown on Table 4.4. 
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Table 4.4 Univariate and multivariate linear regression analyses of independent 
variables on the T0VL as dependent variable 
 
Covariate 
T0VL Univariate T0VL Multivariate 
β P β P 
Age (yrs) 0.007 
(-0.004 to 0.01) 
0.22 - - 
Gender 0.24 
(-0.002 to 0.5) 
0.052 0.2 
(-0.07 to 0.4) 
0.15 
Ethnicity -0.16 
(-0.3 to 0.01) 
0.068 -0.1 
(-0.3 to 0.06) 
0.20 
EFV (μg/ml) -0.00002  
(-0.00005 to 0.00002) 
0.36 - - 
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4.4 DISCUSSION 
TDM is the practice of managing plasma drug concentrations and this intervention 
can potentially improve inadequate antiretroviral dosing in the treatment of HIV 
infection. Variability in plasma concentrations may result from several factors, 
including adherence, absorption, metabolism, clearance, and drug-drug interactions 
(Back et al., 2002). EFV concentration ranges of 1–4mg/L are achievable thresholds, 
with evidence for improved viral suppression and reduced CNS toxicity (Marzolini et 
al., 2001; Stahle et al., 2004). This relationship justifies the use of EFV plasma 
quantification in HAART management and optimization.  
 
In this chapter, the patients’ demographics including age, gender, and ethnicity had no 
influence on EFV plasma concentrations. Previous studies showed the CYP2B6 516G> 
T polymorphism increased plasma efavirenz concentrations (Gounden et al., 2010; 
Puthanakit et al., 2009; To et al., 2009). Plasma concentrations of efavirenz were also 
associated with body weight in HIV-positive individuals (Poeta et al., 2011). Using 
sensitive testing methods, HIV-1 RNA can be detected in plasma in a large proportion 
of patients receiving HAART and showing a VL < 50 copies/ml for many years 
(Dornadula et al., 1999; Havlir et al., 2003). Viral kinetics studies have shown that 
plasma HIV-1 RNA levels decline to < 50 copies/ml within approximately 12 weeks 
of starting therapy (Di Mascio et al., 2003). Once below 50 copies/ml, the levels 
continue to decline for several months before reaching a plateau of residual viremia at 
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around 3-10 copies/ml (Maldarelli et al., 2007). In a previous study, EFV and 
indinavir decreased the HIV-1 RNA levels of patients from 10 copies/ml to levels < 
2.5 copies/ml (Havlir et al., 2003). Conversely, HIV-1 RNA levels of patients with a 
triple HAART regimen have been seen to increase gradually above 50 copies/ml when 
they used a monotherapy with ritonavir-boosted atazanavir (Tobin et al., 2005). 
Furthermore, raltegravir intensification of a three-drug suppressive HAART regimen 
resulted in a specific and transient increase in episomal DNAs in a large percentage of 
HAART-suppressed subjects (Buzon et al., 2010). Finally, HIV-1 genetic evolution 
has been observed with HIV-1 RNA levels between 6.5 and 50 copies/ml (Shiu et al., 
2009). For all patients with VL < 50copies/ml in this study, a significant difference of 
EFV plasma concentration between HIV RNA detected and undetected was observed.  
 
However, no correlation between VL and EFV plasma concentration emerged in 
univariate and multivariate analysis. A trend towards correlation of gender and 
ethnicity with viral load was observed in univariate analysis while age, gender and 
ethnicity of patients were all shown not to influence on viral load of plasma in 
multivariate analysis. A study in univariate analysis showed a similar results with ours 
in gender (p = 0.77) and ethnicity (p = 0.34) but black Africans presented with a viral 
load lower than that of patients in other groups in multivariate analysis (Saul et al., 
2001). Conversely, previous study also showed Women had higher viral loads than 
men when CD4 T-cell counts were at most 50cells/μl (Donnelly et al., 2005). 
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In summary, EFV plasma concentrations influenced the viral load in plasma in this 
cohort of patients from the UK. However, no correlation was observed between 
patients’ demographics and EFV plasma concentration. Since intracellular 
concentrations of drug may be more important for viral suppression future studies 
should assess the relationship with concentrations at the intracellular target. 
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5.1 INTRODUCTION 
Combination antiretroviral therapy (cART) is increasingly used in the treatment of 
HIV infection. Therapeutic effect may be limited by toxicity, pill burden, need for 
strict adherence to treatment, emerging prevalence of resistance and the risk of 
developing adverse drug interactions. Effective cART comprises three or more drugs 
from any of the five classes: nucleoside reverse transcriptase inhibitors (NRTI), 
non-nucleoside reverse transcriptase inhibitors (NNRTI), protease inhibitors (PI), 
Integrase inhibitors, and entry inhibitors (EI).  
 
Efavirenz (EFV) is an essential component of the regimens for the treatment of HIV-1 
infection. Recent studies provide evidence for the role of cytochrome P450 (CYP) 
genes, in particular CYP2B6, in relation to EFV pharmacokinetics (Heil et al., 2012). 
CYP2B6 polymorphisms also influence the clinical progression under EFV treatment 
(Elens et al., 2010). Previous studies showed the CYP2B6 polymorphism was 
significantly associated with plasma EFV concentrations (Gounden et al., 2010). 
Particularly, CYP2B6 516 G>T polymorphism significantly affects the drug 
metabolism of EFV (Puthanakit et al., 2009). Another polymorphism, CYP2B6 983 
T>C, is very rare in Caucasians but is also strongly associated with EFV plasma 
concentrations (Wyen et al., 2008). This polymorphism is most common in African 
populations with the highest frequency being reported in Ghana (Mehlotra et al., 
2007). The constitutive androstane receptor (CAR) is a nuclear receptor involved in 
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the transcriptional regulation of enzyme expression and may also contribute to the 
inter-individual variability in plasma EFV concentrations (Wyen et al., 2011). 
 
ABCB5 is a plasma membrane-spanning protein that in humans is encoded by the 
ABCB5 gene (Frank et al., 2003). It is an ABC transporter, related to P-glycoprotein 
and is normally expressed in various tissues and cells, and enhanced expression has 
been demonstrated in selected cancers (Setia et al., 2012). Recent work in our 
laboratory has indicated that EFV is a substrate for ABCB5 (unpublished). 
 
Copy number variations (CNVs) are a form of structural variation and alterations of 
the DNA of a genome that results in the cell having an abnormal number of copies of 
one or more sections of the DNA. CNVs are important polymorphisms that can 
modulate gene expression and predispose to various clinical phenotypes (Al-Sukhni et 
al., 2012). CNVs can be caused by genomic rearrangements such as deletions, 
duplications, inversions and translocations. They result in the level of transcription 
being higher or lower than those that can be achieved by control of transcription of a 
single copy (Mefford et al., 2011). Recently, CNVs have been associated with genetic 
disease such as cancer, immune disease and neurological disorders (Al-Sukhni et al., 
2012; Coe et al., 2012; Huber et al., 2011). Of particular interest, a recent study 
indicated that the ABCB5 gene contained functional CNVs (Glessner et al., 2010). 
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The aim of this study was firstly to investigate the frequencies of the Single 
Nucleotide Polymorphisms (SNPs) of CYP2B6 (CYP2B6 516G>T [rs3745274] and 
CYP2B6 983T>C [rs28399499]), the CAR540 C>T (rs2307424) polymorphism and 
CNVs of ABCB5 in a cohort of Ghanaian HIV patients. The impact of these selected 
CYP2B6 and CAR genetic polymorphisms and CNV of ABCB5 on the plasma 
concentrations of EFV in a subset of patients was also assessed. 
 
 
 
 
 
 
 
 
 
 
 
 
 
  CHAPTER 5 
152 
 
5.2 METHODS 
5.2.1 Materials  
EFV was donated by DuPont Pharmaceuticals Company (Wilmington, USA). Blank 
plasma was obtained from the National Blood Service. Acetonitrile (ACN), Methanol 
(MeOH), Ethyl acetate and n-hexane were purchased from VWR International Ltd. 
(Leicestershire, UK). Potassium carbonate (K2CO3) and ammonium acetate were 
purchased from Sigma Aldrich (Poole, UK). Internal standard Ro 31-9564 was 
purchased from Roche Discovery (Welwyn, UK). Deionised water was obtained from 
the reservoir of the Option 4 water purifier (Elga, High Wycombe, Bucks, and UK). 
Chloroform and nuclease free water were purchased from Sigma-Aldrich (Poole, UK). 
Isopropyl alcohol and ethanol were obtained from Fisher Scientific (Loughborough, 
UK). Whole blood DNA extraction kits were purchased from QIAGEN (West Sussex, 
UK). The primers and probes for real-time PCR based allelic discrimination assay and 
the TaqMan copy number assay were obtained from the Assays by Design Service, 
Applied Biosystems (Warrington, UK).  
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5.2.2 Instruments 
The HPLC consisted of a Dionex (Dionex Softron GmbH, Germany) HPLC system 
with a P 680 pump, ASI-100 automated sample injector and UVD170U detector. 
Reversed-phase-liquid chromatography was carried out for EFV using a Hypurity C18 
analytical column, 5μm 150 × 4.6mm from Thermo Electron Corporation (Runcorn, 
UK). 
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5.2.3 Patients Data 
800 patients with confirmed HIV infection were recruited. All patients were receiving 
EFV-based cART. Genotype data were analysed to examine the impact of selected 
polymorphisms in EFV metabolising enzymes on steady state concentrations of 
plasma EFV. ABCB5 CNV data were analysed in a subset of patients (352) to 
investigate the impact of copy numbers on EFV plasma concentrations. To be 
included in the study, patients were aged at least 18 years and those on EFV were 
taking it at the fixed dose of 600mg daily plus two nucleoside reverse transcriptase 
inhibitors and had good pharmacy records and pill counts as surrogates for adherence. 
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5.2.4 Quantification of plasma EFV concentration 
EFV concentrations were determined using high performance liquid chromatography 
(HPLC) with UV detection. The limit of detection was 110ng/ml and the upper limit 
was 8000ng/ml. Analyses were conducted as outlined in section 4.2.4.  
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5.2.5 Genotyping of CYP2B6 and CAR polymorphisms 
Genomic DNA was extracted from serum using a kit from QIAGEN according to the 
manufacturer’s instructions as outlined in section 2.2.6. Genotypes for the CYP2B6 
(CYP2B6 G516T and CYP2B6 T983C) and the CAR (CAR C>T [rs2307424]) 
polymorphisms were determined by real-time PCR using standard methodology 
according to the manufacturer’s instructions and as outlined in section 2.2.8.  
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Table 5.1 TaqMan assay IDs and primer-probe sequences for the assays of 
genotype 
 
SNPs TaqMan Assay ID 
CAR540 C_25746794_20 
 Primer-probe sequences 
CYP2B6 G516T Forward: CTTGACCTGCTGCTTCTTCCTA 
Reverse: AGACGATGGAGCAGATGATGTTG 
FAM: TTCCATTCCATTACCG 
VIC: TTCCAGTCCATTACCG 
CYP2B6 T983C Forward: GCCTGAAATGCCTCTTTAAAATGAGATTC 
Reverse: GCGATGTGGGCCAATCAC 
FAM: CTGTTCAATCTCCC 
VIC: CTGTTCAGTCTCCC 
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5.2.6 Copy number assays for ABCB5 
Genomic DNA was extracted from serum using a kit from QIAGEN according to the 
manufacturer’s instructions as outlined in section 2.2.6. Genomic DNA concentrations 
were normalized to 20ng/μl. Samples were prepared for real-time PCR as follows: 
10μl Master mix (qPCR ROX mix), 1μl TaqMan ABCB5 CNVs assay, 1μl copy 
number reference assay RNase P and 3μl gDNA. Reaction mixtures were then made 
up to 20μl final volume using DNase free water.  
 
Thermal cycling conditions consisted of 15 minutes at 95°C followed by 40 cycles of 
15 seconds at 95°C and 1 minute at 60°C. Samples were then held at 4°C. 
Quantification of PCR products occurred in real-time and was analysed using the 
Chromo 4 Real-Time Detection System (MJ Research, INC. Waltham, Massachusetts, 
USA). 
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5.2.7 Statistical analysis 
The plasma concentration of EFV was log10 transformed and given as median (range) 
unless stated otherwise. Distribution of the EFV plasma concentrations was 
determined via Shapiro-Wilk test. The effects of patient demographics and genotypes 
on the EFV plasma concentrations were assessed by Mann-Whitney test (for gender 
and genotype groups) or by simple linear regression (continuous data including age 
and body weight) using Pearson’s rank correlation coefficient. Rho is a 
non-parametric correlation coefficient. A p-value < 0.05 was considered to identify 
groups that were significantly different from each other and a p-value < 0.1 was used 
as a cut off for trend. The genotypes with rare double variants (defined by < 3 in the 
total sample population) were treated as one genotype with the heterozygous variants 
in these analyses. These statistical analyses were conducted using Stats Direct (Stats 
Direct Ltd., Cheshire, UK). Multivariate analysis was conducted to construct a 
predictive model using patient demographic factors and genotypes as independent 
variables and EFV plasma concentrations as the dependent variable. Dichotomous 
variables, including gender, were coded as 0 for female and 1 for male, while CYP2B6 
516G>T, CYP2B6 983T>C, CAR C>T (rs2307424) genotypes were coded as 0, 1 and 
2 for homozygous wild type, heterozygous variants and homozygous variants 
respectively, while age and weight were included as continuous variables. Then 
univariate analysis was used to select the independent variables with p< 0.2 to be 
included in the multivariate analysis. These statistical analyses were conducted using 
SPSS 20 (SPSS Inc., Chicago, USA) 
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5.3 RESULTS 
5.3.1 Patient demographics 
800 patients were recruited and the patient characteristics, including age, gender 
weight and height, were obtained from medical records. The average age of study 
participants was 40.2 years old with a range from 17 to 68 years old. The ratio of 
female to male was 1.2:1. The average body weight of patients was 59.7kg with a 
range from 34kg to 102kg. The body height of patients was from 110cm to 186cm and 
the average was 160.9cm. 72.3% of patients were on cART while 27.7% were naïve 
to therapy at the time of sampling. Of those on cART, 90.1% of patients were on 
EFV-based therapy. Demographic data are presented in Table 5.2. 
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Table 5.2 demographics of patients in Ghana cohort 
Demographics 
Age (y) Average 40.2 
Range 17 to 68 
Gender (n, %) Male 363，45.4 
Female 431，53.8 
Body weight (cm) Average 59.7 
Range 34 to 102 
Body height (kg) Average 160.9 
Range 110 to 186 
cART (n, %) Efavirenz-based 521, 90.1 
Nevirapine-based 56, 9.7 
Nelfinavir-based 1, 0.2 
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5.3.2 Frequencies of SNPs in EFV metabolising enzymes 
Of the 800 samples from which genomic DNA were extracted, genotyping was 
successful for 88.1% of CYP2B6 G516T, 87.6% of CYP2B6 T983C and 86.9% of 
CAR540 polymorphisms respectively. Genotype frequency and allele frequency of 
these polymorphisms analysed in this study are shown in table 5.3. Overall, the 
genotype frequencies of CYP2B6 G516T were 29.8% of GG, 44.3% of GT and 25.9% 
of TT; CYP2B6 T983C were 90.5% of TT, 9.4% of CT and 0.1% of CC; and CAR 
C>T (rs2307424) were 86.5% of CC, 13% of CT and 0.5% of TT (Table 5.3). Allele 
frequencies for CYP2B6 G516T were allele 0.52 for the G and 0.48 for the T allele, 
CYP2B6 T983C were 0.95 for the T allele and 0.05 for the C allele and CAR540 were 
0.93 for the C allele and 0.07 for the T allele (Table 5.3). The observed genotype 
frequency was in Hardy-Weinberg equilibrium. 
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Table 5.3 the genotype and allele frequencies of selected SNPs of enzymes 
involved in metabolism of EFV 
 
SNPs Genotype Frequency n (%) Allele Frequency % 
CYP2B6 
516G>T 
GG 
226 (29.8) 
GT 
336 (44.3) 
TT 
196 (25.9) 
G 
52.0 
T 
48.0 
CYP2B6 
983T>C 
TT 
684 (90.5) 
TC 
71 (9.4) 
CC 
1 (0.1) 
T 
95.2 
C 
4.8 
CAR540 
C>T  
CC 
647 (86.5) 
CT 
97 (13) 
TT 
4 (0.5) 
C 
93.0 
T 
7.0 
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5.3.3 SNPs impact on plasma EFV concentrations 
The impact of each selected SNPs on the mid-dose plasma concentration of EFV is 
depicted in Figures 5.1 to 5.3. Concentration of EFV was significantly higher in 
individuals homozygous for the variant allele (TT) at position 516 of the CYP2B6 
gene (TT [n=128]: 1800ng/ml vs 1073ng/ml and 929ng/ml for GT [n=226] and GG 
[n=120] individuals; p<0.0001). Similarly, concentration of EFV was significantly 
higher in individuals homozygous or heterozygous for the variant allele (CC/TC) at 
position 983 of the CYP2B6 gene ([CC n=1 and TC n=42]: 3235ng/ml vs 1053ng/ml 
for TT [n=429] individuals; p<0.0001). However, the concentration of EFV was not 
significantly different in individuals homozygous for the variant allele of CAR540 
([TT] n=1 or heterozygous for the variant allele [CT] n=66 1004.05ng/ml and for 
normal CC [n=395] individuals 1130ng/ml, p=0.3). 
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Figure 5.1 the impact of polymorphism of CYP2B6 516G>T on the plasma 
concentrations of EFV. The lines indicate the median values. 
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Figure 5.2 the impact of polymorphism of CYP2B6 983T>C on the plasma 
concentrations of EFV. The lines indicate the median values. 
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Figure 5.3 the impact of polymorphism of CAR540 C>T on the plasma 
concentrations of EFV. The lines indicate the median values. 
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5.3.4 CNVs of ABCB5 impact on plasma EFV concentrations 
Copy number variation in the ABCB5 gene was identified in 4 patients with a single 
copy, 197 patients with two copies, 14 patients with three copies, 4 patients with four 
copies and 1 with six copies. There were no significant associations between ABCB5 
copy number and plasma concentrations of EFV (Figure 5.4).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  CHAPTER 5 
169 
 
 
 
Figure 5.4 the impact of CNVs of ABCB5 on the plasma concentrations of EFV. 
The lines indicate the median values. 
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5.3.5 Impact of patient demographics on EFV plasma concentrations 
The influence of patient demographics (including gender, age, body weight and height) 
on EFV plasma concentration was investigated. There was no significant association 
between gender and EFV plasma concentrations (Figure 5.5). A negative correlation 
between body weight and EFV plasma concentrations was identified (Figure 5.6). 
Meanwhile, no other correlations were found between patient demographics and EFV 
plasma concentration in the Ghanaian cohort (Figure 5.6). 
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Figure 5.5 Impact of gender on EFV plasma concentration in Ghana cohort. The 
lines indicate the median values. 
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Figure 5.6 Impact of age, body weight, body height with EFV plasma 
concentration in Ghana cohort 
Rho = -0.02 
p = 0.62 
2 
2.5 
3 
3.5 
4 
4.5 
0 10 20 30 40 50 60 70 80 
EF
V
 P
la
sm
a 
C
o
n
ce
n
tr
at
io
n
 (
µ
g/
m
l)
 
Age (yrs) 
Rho = -0.12 
p = 0.007 
2 
2.5 
3 
3.5 
4 
4.5 
30 40 50 60 70 80 90 100 110 
EF
V
 P
la
sm
a 
C
o
n
ce
n
tr
at
io
n
 (
µ
g/
m
l)
 
Body Weight (kg) 
Rho = -0.002 
p = 0.96 
2 
2.5 
3 
3.5 
4 
4.5 
100 120 140 160 180 200 
EF
V
 P
la
sm
a 
C
o
n
ce
n
tr
at
io
n
 (
µ
g/
m
l)
 
Body Height (cm) 
  CHAPTER 5 
173 
 
5.3.6 Multivariate analysis  
The median plasma concentration of EFV was 1087μg/ml with a range from 
110.0μg/ml to 12,146.0μg/ml and a coefficient of variation of 113%. In univariate 
analysis, body weight in kilograms (p = 0.008), polymorphisms in CYP2B6 G516T (p 
= 2.5 x 10
-7
) and CYP2B6 T983C (p = 4.5 x 10
-14
) were all significantly correlated 
with log EFV concentration (Table 5.4). In multivariate analysis, body weight, 
CYP2B6 G516T polymorphism and CYP2B6 T983C polymorphism were identified as 
independently associated with EFV exposure as shown in Table 5.4.  
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Table 5.4 Univariate and multivariate linear regression analyses of independent 
variables on the log concentration of EFV as dependent variable 
 
Covariate Univariate P Multivariate P 
Multivariate  
coefficient (B) 
Age (yrs) 0.23 - - 
Gender 0.84 - - 
Weight (kg) 0.008 0.016 -0.11 
Height (cm) 0.45   
CYP2B6 516G>T  2.5 x 10
-7
 1.4 x 10
-11
 0.32 
CYP2B6 983T>C 4.5 x 10
-14
 1.3 x 10
-15
 0.38 
CAR540 C>T   0.12 0.07 0.08 
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5.4 DISCUSSION 
CYP2B6 is one of the most polymorphic cytochrome P450 genes in humans with over 
100 described polymorphisms and distinct ethnic frequencies (Zanger et al., 2007). 
Previous studies show that the CYP2B6 G516T and CYP2B6 T983C polymorphisms 
are in association with EFV and nevirapine plasma concentration (Calcagno et al., 
2011; Haas et al., 2009; Rakhmanina et al., 2010; Rotger et al., 2007; To et al., 2009; 
Wyen et al., 2008). The CAR540 polymorphism has previously been shown to 
influence early treatment discontinuation of EFV in German patients (Wyen et al., 
2011). The effect of CYP2B6 G516T and CYP2B6 T983C was confirmed in this 
chapter while no significant association emerged for CAR540 and EFV plasma 
concentrations. There may be differences in the functionality of this polymorphism 
between different ethnicities. 
 
A comprehensive analysis of the genotypes frequency has been performed. The 
frequency of CYP2B6 (G516T) TT was 0.26 in our cohort, similar to previous studies 
which showed 0.19 in a Ghanaian cohort and 0.23 in a South African cohort 
(Gounden et al., 2010; Kwara et al., 2009). The T allele frequency of CYP2B6 
(G516T) was 0.48 in the current Ghanaian cohort. And the CYP2B6 (G516T) had a 
frequency of 0.31 in other African populations and 0.16 in Chinese (Brown et al., 
2012; Chen et al., 2010). Furthermore, the genotype frequency of CYP2B6 (T983C) 
TC was 0.09 in the current cohort similarly previous study which identified a 
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frequency of 0.08 (Kwara et al., 2009). 
 
Copy number variation (CNV) involving deletion or multiplication of DNA segments 
is a primary source of variation in the human genome (Sebat et al., 2004). In this 
study, the copy number variation of ABCB5 had no relationship with the plasma 
concentration of EFV. Although previous studies in our laboratory have shown that 
EFV is a substrate for ABCB5 (unpublished), the lack of association between CNV 
and efavirenz PK in this chapter and ABCB5 based upon data in Chapter 6 indicated 
that efavirenz is unlikely to be a transported substrate of ABCB5.  
 
Meanwhile, no correlation has been found between ABCB5 genetics and EFV plasma 
concentrations in the literature. However, several studies have investigated whether 
CCL3L1 CNV influences the risk of HIV-1 infection, but there are no studies that 
have shown CNVs to be important for HIV drugs (Liu et al., 2010). Recent studies 
have suggested an increasing role for CNVs in many diseases (Fanciulli et al., 2010; 
Levy et al., 2012) because a number of genes involved in drug metabolism exhibit 
CNVs (Gaedigk et al., 2012). For example, CYP2D6 CNVs can result in reduced or 
increased metabolism of many clinically used drugs (Sheng et al., 2007). The 
investigation of CYP2D6 allelic distributions and CNVs in ethnic populations can be 
an important determinant for future dose optimization (Gaedigk et al., 2011; Kim et 
al., 2010; Kim et al., 2012; Sheng et al., 2007). 
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Age, gender, body weight and height are also important factors which may influence 
drug pharmacokinetics. In this study, a negative correlation was found between the 
body weight and the EFV plasma concentration in univariate analysis. Previous 
studies showed a significant and inverse correlation between efavirenz concentrations 
and body weight in Brazilian and Thai cohort (Manosuthi et al., 2009; Poeta et al., 
2011). Obesity was also reported that it represented a risk factor for antiretroviral 
therapy underdosing (de Roche et al., 2012) 
 
In conclusion, the polymorphisms of body weight, CYP2B6 G516T and CYP2B6 
T983C affect EFV plasma concentrations in Ghanaian patients. However, CAR540 did 
not exert a significant impact on EFV exposure in this cohort of Ghanaian HIV-1 
infected patients on EFV-based therapy. The lack of association between CNV and 
efavirenz pharmacokinetics support ABCB5 does not substrate for efavirenz. 
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transcellular permeability in Caco-2, 
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6.1 INTRODUCTION 
As in other diseases, development of new antiretroviral drug candidates is severely 
hampered by poor solubility. Insolubility is limited not only to new molecules but also 
prevents many existing therapies from optimally performing. Nanotechnology 
represents a major opportunity to enhance the performance of existing medicines. 
New non-attrition techniques have been developed in Liverpool to produce 
Nanomedicines that overcome some limitations associated with conventional 
formulations. Nanoparticle preparation is currently subject to patent fillings and 
cannot be disclosed. However, they were produced using a previously published 
synthesis (Zhang et al., 2008). Application of these techniques to current antiretroviral 
drugs offers the potential to generate next generation therapies with enhanced clinical 
and patient benefits. 
 
The majority of antiretroviral drugs are orally administered and their absorption from 
the gastrointestinal tract is pivotal for their success in therapy. The rate and extent of 
intestinal absorption of drug products is dependent upon physicochemical (e.g. 
solubility, size, charge and surface area), physiological (e.g., stomach emptying, 
intestinal motility and membrane permeability), formulation (e.g., dosage form, 
dissolution, excipients and stability) and protein activity (e.g., metabolism, efflux and 
uptake) (Volpe, 2011). Membrane permeability is one of the most important factors in 
intestinal absorption and can be investigated using specific cell lines such as Caco-2 
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and Madin–Darby canine kidney (MDCK) cells. 
 
The Caco-2 cell line, isolated from a human colon adenocarcinoma, differentiates into 
enterocytes and forms polarized monolayers of columnar epithelial cells with tight 
junctions and a brush border and are actively used as a model by industry (Elsby et al., 
2008). Caco-2 cell monolayers have high transepithelial electrical resistance (TEER) 
values and the advantage of containing both passive and active (uptake, efflux) 
permeability mechanisms (Table 6.1). The MDCK cells, isolated from canine distal 
renal tissue, also differentiate into columnar epithelium and form tight junctions. The 
MDCK cells have lower TEER and shorter culture times than Caco-2 cells (Table 6.1). 
The Caco-2 and MDCK cell lines have a relationship to human intestinal absorption 
and drug permeability as they can be used to model passive diffusion (paracellular, 
transcellular), carrier-mediated uptake, and carrier-mediated efflux and so on. 
Therefore, they are rapid tools to screen the drug permeability and transport at the 
cellular level. However, there are some limitations to using them because some 
substances have very low aqueous solubility, toxic drugs adversely affect results of 
permeability measures, physiological factors are difficult to predict and proteins and 
transporters can have different expression in primary cells compared to these cell lines 
(Zheng et al., 2011).  
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Caco-2 cells have been shown to express both efflux (ABCB1, ABCG2 and ABCC 
subfamily of transporters) and influx (multiple proteins of OATP subfamily of 
transporters, PepT1, OCT1-3) transporters (Majer et al., 2012; Mease et al., 2012; 
Prime-Chapman et al., 2004; Seithel et al., 2006). MDCK cells express 
ABCB1(Mease et al., 2012).  
 
Very little is known about transporters capable of influx and efflux of efavirenz (EFV) 
in intestine or liver. Recent work in Liverpool has indicated that EFV may be a 
substrate for ABCB5 (unpublished observation). ABCB5 is an ATP-binding cassette 
(ABC) efflux transporter that is of the same sub-family as ABCB1 (Frank et al., 2005). 
like ABCB1, ABCB5 has been shown to be expressed in intestine (Taipalensuu et al., 
2001) and may therefore influence absorption of EFV. However, it should be noticed 
that in chapter 5, no association of ABCB5 CNVs with EFV plasma concentration 
was observed in patients from Ghana. 
 
In this chapter, the Caco-2 cell line was used to evaluate the permeability of ten 
nanodispersions of lopinavir (LPV) (designated NanoLPV1-NanoLPV10) compared 
with an aqueous solution of LPV. Meanwhile, the transcellular permeability of six 
nanodispersions of efavirenz (designated NanoEFV1 to NanoEFV6) was compared 
with an aqueous solution of EFV in MDCKII as well as the MDCKII-ABCB5 
(ABCB5-overexpressing) cell line.  
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Table 6.1 Cell line characteristics 
 Caco-2 MDCK 
Cell source Human colon adenocarcinoma Canine kidney 
Cell morphology Intestinal epithelium Distal tubule epithelium 
Cell culture time 14–28 days  3–7 days 
TEER value 600 200 
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6.2 METHODS 
6.2.1 Materials 
The Caco-2 cell line was purchased from European collection of cell cultures 
(ECACC No.286010202). The MDCKII cells were a kind gift from Prof. P. Borst 
(Amsterdam Netherlands). And the cells were counted using a NucleoCounter 
(ChemoMetec, Denmark) cell counter. MDCKII-ABCB5 was developed in-house as 
part of a separate project. A Millicell Electrical Resistance System (Fisher Scientific, 
Leicestershire, UK) was used for measuring Monolayer TEER. LPV was provided by 
Abbott Laboratories (Chicago, USA), EFV by DuPont Bristol Myers Squibb (New 
Brunswick, NJ, USA). Radiolabelled LPV (
3
H LPV) and EFV (
14
C EFV) were 
purchased from Moravek Biochemicals, Inc. (Brea California, USA). Dulbecco 
modified Eagle medium (DMEM), foetal bovine serum (FBS), Hanks buffered salt 
solution (HBSS) and Trypsin-EDTA solution were purchased from Sigma Aldrich 
(Poole, UK). Ultima Gold liquid scintillation cocktail was obtained from Packard 
(Groningen, Netherlands).  
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6.2.2 Cell culture  
Caco-2 cells were cultured in DMEM supplemented with FBS (15%v/v) and MDCKII 
and MDCKII-ABCB5 cells were grown in DMEM supplemented with L-glutamine, 
penicillin/streptomycin (1%v/v) and FBS (10%v/v). The cells were grown and 
routinely seeded in tissue culture treated flasks in a humidified chamber (37°C, 10% 
CO2 incubator) and harvested by regular trypsinisation. The medium was changed 
every 2 to 3 days until the confluence of the cell monolayer was achieved. 
Trypsinisation involved decanting the media, followed by washing twice with 20 ml 
HBSS and the detachment of the monolayer by addition of 10ml Trypsin-EDTA. The 
cells were then incubated for 10 minutes. The resulting suspension was centrifuged 
(2000 g × 5 min, 4°C), the supernatant removed and the resulting pellet re-suspended 
in 10 ml of fresh DMEM, counted using a cell counter and ~ 7 million cells 
transferred to each new flask and made to 35 ml with DMEM. 
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6.2.3 Storage of Cells 
The cells were trypsinised as described earlier after attaining confluence (section 
6.2.2). The pellets were then re-suspended in DMEM, counted using a cell counter 
and centrifuged (2000 g × 5 min, 4°C). The cells were then re-suspended in warm 
FBS (FBS + 10%v/v DMSO), mixed thoroughly and made up to a concentration of 5 
× 10
6
 cells per ml. 1 ml of cell suspension was then transferred to pre-labelled 1.5 ml 
cryovials and frozen at -80°C for use as and when required. The viable semi-frozen 
cells were thawed by placing the cryovials rapidly in a waterbath (37°C) or by simply 
holding the vials in the hands for a few minutes and re-suspending the pellets in 9 ml 
DMEM followed by culturing as described in section 6.2.2. 
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6.2.4 Cell seeding 
The cells were trypsinised as described in section 6.2.2, and after centrifugation the 
pellet was re-suspended in fresh DMEM, and the cells counted using a cell counter. A 
volume of DMEM was added to give a cell count of 1.4 × 10
5
 cells per ml, and cells 
were seeded on transwell culture plates at density of ~35,000 cells per well for the 
Caco-2 cell line and ~100,000 cells per well for the MDCKII and MDCK-ABCB5 
cell lines. The plates were then incubated at 37°C and 10% CO2 in a humidified 
chamber and the media was changed every 2-3 days, by aspirating using a suction 
pump and replacing with an equal volume of DMEM. Caco-2 cell monolayers were 
used for transport studies 15–21 days post seeding over passage numbers 27–36, 
while MDCKII and MDCK-ABCB5 cell lines were used for transport studies 7–12 
days post seeding over passage numbers 10–16. The TEER across the cell monolayer 
was monitored using a Millicell Electrical Resistance System to assess cell monolayer 
integrity and the monolayer was considered appropriate for experiments when the 
TEER values were typically above 600 cm
2
 for the Caco-2 cell line and above 200 
cm
2
 for MDCKII and MDCKII-ABCB5 cell lines. 
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6.2.5 Permeability assays 
Prior to transport studies, the medium was removed from all apical and basolateral 
compartments of the transwells and washed with HBSS. Cell monolayers were 
pre-incubated in transport buffer (HBSS containing 25mM HEPES and 0.1% (w/v) 
bovine serum albumin, pH 7.4) for 10–15 min at 37°C prior to the addition of donor 
and receiver solutions. Following this pre-incubation period, HBSS containing 10μM 
of the desired drug was added to the donor compartments of transwells situated on 
either the apical (total volume = 250 ml) or basolateral (total volume = 600 ml) side 
of the monolayer. Transport buffer was added to the corresponding receiver 
compartments. Permeability in each direction was done in quadruplicate. The 
transport of the compound across the monolayer is monitored over a 60 min time 
period in incubator (37°C, 10% CO2 incubator), and 150μl of samples from the apical 
(basolateral to apical) or basolateral (apical to basolateral) compartments were taken 
and quantified by using a liquid scintillation counter. 
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6.2.6 Statistical analysis 
The apparent permeability coefficient (Papp) is determined from the amount of 
compound transported per time. The values are expressed as cm/second and are 
calculated according to the following equation: 
Papp = ((dQ/dt) × V) / (A × C0) 
Where dQ is the concentration variations, dt is the time variations, V is the sample 
volume (0.6 ml for apical to basolateral, 0.25 ml for basolateral to apical), A is the 
exposed surface area (0.3 cm
2
) and C0 is concentration at the start (10μM).  
 
The results were presented as mean ± standard deviation (SD) of four experiments 
with 95% confidence intervals for differences between the means where appropriate. 
The means of Papp were then used to calculate efflux ratio (ER = Papp 
basolateral-to-apical/Papp apical-to-basolateral) 
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6.3 RESULTS 
6.3.1 Impact of nanoformulation on the permeability of LPV in Caco-2 cells 
The bi-directional Papp of ten nanodispersions of LPV (NanoLPV1 to NanoLPV10) 
and an aqueous solution of LPV in Caco-2 cells were shown in figure 6.1. Only two 
nanodispersions (NanoLPV6 and 9) had a higher permeability than aqueous LPV not 
only in basolateral to apical direction but also in the apical to basolateral direction. All 
nanodispersions of LPV (except NanoLPV4) had a higher permeability than the 
aqueous LPV in the apical to basolateral direction. However, other nanodispersions of 
LPV (NanoLPV1, 2, 3, 4, 5, 7, 8 and 10) exhibited a lower permeability than aqueous 
LPV in basolateral to apical direction. The efflux ratio of aqueous LPV was 1.1, while 
efflux ratios of LPV nanodispersions were ranged from 0.41 to 0.95. 
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Figure 6.1 comparing the permeability of nanodispersions and aqueous LPV in 
the Caco-2 cell line.  
  CHAPTER 6 
192 
 
6.3.2 Impact of nanoformulation on the permeability of EFV in MDCKII and 
MDCKII-ABCB5 cells  
The bi-directional Papp of six nanodispersions of EFV (NanoEFV1 to NanoEFV6) and 
an aqueous solution of EFV in MDCKII and MDCKII-ABCB5 cell lines were shown 
in figure 6.2 and 6.3. All nanodispersions had a lower permeability than the aqueous 
EFV in both apical to basolateral and basolateral to apical directions by using 
MDCKII cells. In MDCKII-ABCB5 cell lines, the nanotechnology had a negative 
effect on EFV permeability in both apical to basolateral and basolateral to apical 
directions in the MDCKII-ABCB5 cell lines (Figure 6.3). However, NanoEFV4 had a 
higher permeability than the aqueous EFV in apical to basolateral direction (Figure 
6.3). The efflux ratio of aqueous LPV in MDCKII and MDCKII-ABCB5 cell lines 
was 0.18 and 0.15, respectively. The efflux ratios of LPV nanodispersions were 
ranged from 0.10 to 0.23 in MDCKII cell lines and 0.05 to 0.21 in MDCKII-ABCB5 
cell lines. 
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Figure 6.2 comparing the transcellular permeability of nanodispersions and 
aqueous EFV in the MDCKII cell line.  
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Figure 6.3 comparing the permeability of nanodispersions and aqueous EFV in 
the MDCKII-ABCB5 cell line.  
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6.3.3 Impact of ABCB5 on the permeability of nanodispersions and aqueous 
solution of EFV 
The bi-directional Papp of nanodispersions of EFV and an aqueous solution of EFV in 
MDCKII and MDCKII-ABCB5 cell lines were shown in figure 6.4. The bi-directional 
permeability of EFV nanodispersions (NanoEFV1-3) and aqueous EFV were higher 
in both MDCKII cell lines than the permeability in MDCKII-ABCB5 cell lines. Two 
nanodispersions of EFV (NanoEFV4 and 6) had a lower permeability in MDCKII cell 
lines from apical to basolateral direction but a higher permeability from basolateral to 
apical direction. Conversely, the permeability of NanoEFV5 was higher in MDCKII 
cell lines from apical to basolateral direction but a lower from basolateral to apical 
direction. ABCB5 increased the permeability of Two nanodispersions of EFV 
(NanoEFV4 and 6) from apical to basolateral direction were observed. Conversely, 
the permeability of NanoEFV5 was increased by the ABCB5 from basolateral to 
apical direction. The efflux ratios of EFV nanodispersions and aqueous EFV were 
ranged from 0.10 to 0.23 in MDCKII cell lines and 0.05 to 0.21 in MDCKII-ABCB5 
cell lines. 
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Figure 6.4 comparing the permeability of nanodispersions and aqueous EFV in 
MDCK and MDCKII-ABCB5 cell line.  
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6.4 DISCUSSION 
The aim of this chapter was to investigate the impact of Nanomedicine on the 
permeability of antiretroviral drugs in cell lines. LPV permeability in the Caco-2 cell 
line was increased by nanoformulation into nanodispersion. 90% of the 
nanodispersions had a higher permeability than aqueous drug in apical to basolateral 
direction. 10% of LPV were increased permeability by nanoformulation in both apical 
to basolateral and basolateral to apical directions. Meanwhile, the bi-directional 
permeability of EFV was decreased by nanoformulation in both MDCKII and 
MDCKII-ABCB5 cell lines. 
 
In a previous study, some other nanotechnologies have been used to enhance drug 
performance. For example, lipid nanocarriers improved paclitaxel transport through 
Caco-2 cell monolayers by using vesicle-mediated transcytosis (Roger et al., 2009). 
Permeability experiments of Sadighi et al revealed that furosemide/HP-betaCD and 
ranitidine HCl/HP-betaCD nanoformulations greatly induced the opening of tight 
junctions and enhanced drug transition through Caco-2 monolayers (Sadighi et al., 
2012). 
 
Furthermore, we also compared efficiency of EFV permeability in MDCKII and 
MDCKII-ABCB5 cell lines and ABCB5 decreased the bi-directional permeability of 
EFV were observed. Although previous studies in our laboratory have shown that 
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EFV is a substrate for ABCB5 (unpublished). The data presented in this chapter 
indicate that ABCB5 is not able to transport EFV neither nanodispersions nor aqueous 
solution. In previous study, the MDCKII-ABCB1 and MDCKII-ABCC2 cells have 
significantly increased LPV efflux ratio relative to the parental cells due to the 
apically directed transport by ABCB1 and ABCC2, respectively (Agarwal et al., 
2007). However, the study of Janneh et al showed that ABCB1 expression had no 
effect on the accumulation of EFV and nevirapine in MDCKII and MDCKII-ABCB1, 
while ABCC1/2 expression and OATP-like transporters (possibly OATP3A1) may 
have greater influence on the accumulation of EFV in MDCKII and MDCKII-ABCB1 
(Janneh et al., 2009). 
 
In conclusion, nanoformulation improved LPV permeability across the Caco-2 cell 
line but decreased the permeability of EFV across MDCKII and MDCKII-ABCB5 
cell lines. ABCB5 is not able to transport EFV neither nanodispersions nor aqueous 
solution. The ability to change permeability of drugs based on the formulation of solid 
drug nanoparticles is worthy of further study in order to improve drug delivery and 
drug distribution.  
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Concluding Discussion 
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Current antiretroviral therapy consists of a combination of at least three drugs and has 
dramatically improved the prognosis of patients infected with HIV. However, viral 
replication during therapy can lead to the selection of drug resistant viruses (Cressey 
et al., 2007). Resistance to antiretroviral therapy has been documented for every class 
of antiretroviral drug including NRTIs, NNRTIs, PIs and inhibitors of viral fusion, 
entry and integration (Boyd et al., 2010). Therefore, currently available therapy aims 
to suppress HIV replication for as long as possible thus delaying the progressive 
destruction of the immune system and postponing the occurrence of opportunistic 
infections and the onset of AIDS. The failure of antiretroviral therapy may be due to 
pharmacological factors such as first pass metabolism and inadequate penetration into 
HIV replication-competent cells. This thesis investigated the pharmacological factors 
such as drug transporters (efflux and influx) and metabolism enzymes.  
 
Drug transporters and metabolism enzymes played complementary roles in drug 
absorption, distribution, metabolism and excretion by biotransformation and 
counter-transport, particularly in the intestine (Benet, 2009), while nuclear receptors 
as transcription factors regulate the expression of drug transporters and metabolism 
enzymes. In chapter 2, a positive correlation between nuclear receptors expression 
and the expression of ABC transporters and OATP transporters in intestine were 
observed. According to the Les Benet’s study, when nuclear receptors increased the 
expression of ABC transporters these efflux transporters increased presentation of 
drug to CYP3A4 and more metabolism as a result of cycles of efflux (Benet, 2009). 
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Nuclear receptors also improved the expression of influx OATP transporters to 
increased presentation of drug to CYP3A4. However, a significant negative 
correlation was found between the gene expression of nuclear receptors and 
cytochrome P450 enzymes in intestine in chapter 3. In previous study, positive 
correlation between the gene expression of nuclear receptors and cytochrome P450 
enzymes in liver has been reported (Chang et al., 2003; Lamba et al., 2010; Vyhlidal 
et al., 2006). The reasons for this difference between liver and intestine may involve 
differences between expressions of other transcription factors such as Vitamin D 
between these tissues. In literature, PXR dominantly controls CYP3A4 inducibility in 
the liver, whereas Vitamin D receptor transactivates CYP3A4 in the intestine by 
secondary bile acids (Pavek et al., 2010). 
 
There have been a number of recent studies that investigate polymorphisms of genes 
that could potentially impact on gene expression of drug transporters and metabolism 
enzymes. The PXR63396 polymorphism has been reported to be associated with PXR 
and CYP3A4 gene expression (Schipani et al., 2010). PXR promoter and intron 1 
SNPs are also associated with PXR target gene expression (CYP3A4) in donor livers 
and cultured hepatocytes (Lamba et al., 2008). Another PXR polymorphism (PXR 
A566C) was significantly associated with CYP3A4 RNA expression in colon tumor 
(King et al., 2007). CYP2B6 C1459T significantly reduced CYP2B6 expression in 
liver (Lang et al., 2001), while CYP3A4 A392G has been shown to be in an 
association with CYP3A4 gene expression (Svard et al., 2010). CYP2B6 C1459T was 
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also associated with the lowest level of CYP2B6 activity in the livers of females 
(Lamba et al., 2003). In chapter 2, a statistically significant association emerged 
between PXR63396 polymorphism and the expression of ABCB1 and ABCC2 in 
intestine and PXR44477 polymorphism was associated with ABCC10 expression in 
intestine. However, no impact of PXR44477, PXR69789 and PXR63396 and CAR 
C>T (rs2307424) polymorphisms on the gene expression of OATP transporters and 
cytochrome P450 enzymes in intestine was found. The polymorphism of CYP2B6 
(G516T and C1459T) and CYP3A4 A392G also had no influence with the gene 
expression of cytochrome P450 enzymes. A clear understanding of the relationship 
between polymorphisms and expression of these proteins is important to rationalise 
differences observed in pharmacokinetics of relevant substrates. 
 
High inter-individual variability in drug concentrations has been demonstrated in 
patients receiving the same dose of antiretroviral drugs (Back et al., 2006). For 
example, EFV interpatient concentration variation is 118% (Marzolini et al., 2001). 
There are many factors that may affect plasma concentrations such as age, gender, 
body weight, ethnicity, genetic factors and so on. Plasma concentrations of the 
NNRTIs have been shown to correlate with virological response (Fabbiani et al., 
2009). Therefore, factors that influence the variability in plasma concentrations may 
cause patients to experience therapeutic failure or toxicity (Justesen, 2006). Chapter 4 
and 5 investigated the factors that influence EFV plasma concentrations in UK and 
Ghanaian cohorts. 
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EFV plasma concentrations are often used to optimise therapy by ensuring minimum 
effective plasma concentrations are achieved (Sun et al., 2010; Yimer et al., 2011). 
Age, gender, body weight and height are important factors which may influence drug 
pharmacokinetics. In a Ghanaian cohort, a negative correlation was found between the 
body weight and the EFV plasma concentration in univariate analysis. It is support by 
previous studies in Brazilian and Thai cohort (Manosuthi et al., 2009; Poeta et al., 
2011). Obesity was also reported that it represented a risk factor for antiretroviral 
therapy underdosing (de Roche et al., 2012). The genetic factors including 
polymorphisms of CYP2B6 G516T and CYP2B6 T983C influenced EFV plasma 
concentrations while the polymorphism of CAR C>T (rs2307424) in the Ghanaian 
cohort. Similarly, CYP2B6 G516T and CYP2B6 T983C polymorphisms were shown 
to be associated with plasma concentrations of EFV in previous studies (Rakhmanina 
et al., 2010; To et al., 2009; Wyen et al., 2008). In the UK cohort, EFV plasma 
concentrations were also found to be associated with viral load in plasma. 
 
One of the reasons for antiretroviral therapy failure is the inability of drugs to reach 
viral reservoir sites such as macrophages (Vyas et al., 2006). This may result in 
relapses and increase likelihood of resistance. Nanodispersion technology is a new 
promising technology that may enable and improve the targeted delivery of 
antiretroviral drugs (Emerich et al., 2006). LPV transcellular permeability in the 
Caco-2 cell line was improved by formulation into nanodispersions. However, for 
EFV the transcellular permeability was decreased for all nanodispersions in MDCKII 
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and MDCKII-ABCB5 cell lines. Comparing efficiency of EFV nanodispersions 
permeability in MDCKII and MDCKII-ABCB5 cell lines indicated that ABCB5 is not 
able to transport EFV when incubated as nanodispersion or dissolved molecule. It is 
support by the copy number variation of ABCB5 had no relationship with EFV 
plasma concentrations in Chapter 5. The MDCKII-ABCB1 and MDCKII-ABCC2 
cells significantly increased LPV efflux ratio relative to the parental cells due to the 
apically directed transport by ABCB1 and ABCC2 respectively (Agarwal et al., 2007). 
ABCC1/2 expression and the OATP3A1 transporter may have greater influence on the 
accumulation of EFV in MDCKII and MDCKII-ABCB1 (Janneh et al., 2009) 
 
 
Figure 7.1 Variations of pharmacological factors that affect treatment response.  
 
DNA sequence 
variation in 
transporters, 
enzymes and 
nuclear receptors  
Variation in 
expression of 
mRNA and 
protein 
Variation in drug 
transport and 
metabolic activity 
Variation in 
plasma drug 
concentrations 
Variation in 
treatment 
response 
  CHAPTER 7 
205 
 
In summary, this thesis examines pharmacological factors involved in antiretroviral 
therapy. Figure 7.1 summarises how these factors impact on the variation in treatment 
response. The variability of DNA sequence in drug transporters, metabolism enzymes 
and nuclear receptors associates with the expression of mRNA and protein. In turn, 
this may impact upon the drug transport and metabolic activity. It also presents data 
that shows the factors that influence drug concentrations, which are important for 
viral suppression. Finally, nonodispersion technology is worthy of further study in 
order to improve drug delivery and distribution.  
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